| Section | Name | Details |
| 01.05.03 | Vedolizumab | See NCL treatment pathways for place in therapy in adults (JFC April 2019). Approved for paediatric use (JFC January 2018). Provider notes
|
| 14.04 | 23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | 23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved as test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (JFC May 2017) Provider notes
|
| 05.03.01 | Abacavir | Provider notes
|
| 05.03.01 | Abacavir + Lamivudine | Provider notes
|
| 05.03.01 | Abacavir + Lamivudine + Zidovudine Trizivir® | Provider notes
|
| 10.01.03 | Abatacept | Approved for:
Provider notes
|
| 08.01.05 | Abemaciclib tabs | See NICE TA for eligibility criteria Provider notes
|
| 08.03.04.02 | Abiraterone | Provider notes
|
| 04.10.01 | Acamprosate | Provider notes
|
| 06.01.02.03 | Acarbose | Provider notes
|
| 10.01.01 | Acemetacin | Provider notes
|
| 02.08.02 | Acenocoumarol | Provider notes
|
| 11.06 | Acetazolamide | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Adjunctive therapy for Open Angle Glaucoma And Ocular Hypertension Provider notes
|
| 11.08.02 | Acetylcholine intra-ocular irrigation Miochol-E®, Miphtel® | Provider notes
|
| 03.07 | Acetylcysteine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 18 | Acetylcysteine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | Acetylcysteine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 11.08.01 | Acetylcysteine 5% + Hypromellose 0.35% eye drops Ilube® | Provider notes
|
| 11.08.01 | Acetylcysteine eye drops - preservative free | Provider notes
|
| 05.03.02.01 | Aciclovir | Provider notes
|
| 11.03.03 | Aciclovir 3% eye ointment | Provider notes
|
| 13.10.03 | Aciclovir 5% cream | Provider notes
|
| 13.05.02 | Acitretin | Provider notes
|
| A5.03.03 | Actisorb Silver 220 | Provider notes
|
| 18 | Activated charcoal | Provider notes
|
| 01.05.03 | Adalimumab | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 10.01.03 | Adalimumab | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for:
Provider notes
|
| 11.99.99.99 | Adalimumab | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 13.05.03 | Adalimumab | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 13.06.01 | Adapalene 0.1% + Benzoyl peroxide 2.5% gel Epiduo® | Provider notes
|
| 13.06.01 | Adapalene 0.1% cream Differin® | Approved for acne (JFC April 2016) Provider notes
|
| 05.03.03.01 | Adefovir Dipivoxil | Provider notes
|
| 02.03.02 | Adenosine 6mg/2mL injection Adenocor® | Provider notes
|
| 02.07.03 | Adrenaline 1:10,000 (100 mcg/1 ml) injection | Provider notes
|
| 03.04.03 | Adrenaline 1:10,000 (100 mcg/1 ml) injection | Provider notes
|
| 03.04.03 | Adrenaline 1:1000 (1 mg/1 ml) injection | Provider notes
|
| 03.04.03 | Adrenaline autoinjector Emerade® | Emerade is preferred to EpiPen for anaphylaxis (JFC August 2015)
Provider notes
|
| 03.04.03 | Adrenaline autoinjector EpiPen® | Emerade is preferred to EpiPen for anaphylaxis (JFC August 2015)
Provider notes
|
| A5.02.07 | Advadraw | Provider notes
|
| A5.02.03 | Advazorb Border | Provider notes
|
| 08.01.05 | Afatinib | Provider notes
|
| 08.01.05 | Aflibercept infusion Zaltrap® | Provider notes
|
| 11.08.02 | Aflibercept intraocular injection Eylea® | Provider notes
|
| 09.08.01 | Agalsidase Alfa and Beta Fabrazyme® | Provider notes
|
| 09.08.01 | Agalsidase Alfa and Beta Replagal® | Provider notes
|
| 20 | Ajmaline | Provider notes
|
| 05.05.01 | Albendazole | Provider notes
|
| 09.02.02.02 | Albumin Solution | Provider notes
|
| 08.01.05 | Alectinib tabs | See NICE TA for eligibility criteria Provider notes
|
| 08.02.04 | Alemtuzumab Lemtrada® | Provider notes
|
| 06.06.02 | Alendronic Acid | Provider notes
|
| 09.06.04 | Alfacalcidol One-Alpha® | Provider notes
|
| 15.01.04.03 | Alfentanil | Provider notes
|
| 07.04.01 | Alfuzosin immediate release | Provider notes
|
| 07.04.01 | Alfuzosin modified release | Provider notes
|
| 09.08.01 | Alglucosidase Alfa Myozyme® | Provider notes
|
| 03.04.01 | Alimemazine tabs/solution | Not recommended for any indication - do not prescribe (JFC November 2018) Provider notes
|
| 02.12 | Alirocumab | Provider notes
|
| 13.05.01 | Alitretinoin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 21.01 | Alitretinoin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Alitretinoin for pityriasis rubra pilaris |
| 10.01.04 | Allopurinol | Provider notes
|
| 09.06.05 | Alpha Tocopheryl Acetate |
Provider notes
|
| 07.04.05 | Alprostadil intracavernous injection Caverject® |
Provider notes
|
| 07.04.05 | Alprostadil intracavernous injection Viridal® Duo |
Provider notes
|
| 07.04.05 | Alprostadil urethral stick MUSE® |
Provider notes
|
| 02.10.02 | Alteplase | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | Alteplase | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 21.01 | Alteplase | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Alteplase for complicated visceral thrombosis |
| 11.99.99.99 | Alteplase 25mcg/0.1ml intravitreal injection | Provider notes
|
| A2.02.02.03 | Altraplen Compact |
Primary care notes For patients who did not tolerate first-line choices and lower volume is indicated or fluid restricted- see Primary Care Guidance |
| 13.12 | Aluminimum chloride 20% Anhydrol Forte® | Provider notes
|
| 13.12 | Aluminimum chloride 20% Driclor® | Provider notes
|
| 20 | Aluminium acetate 8% or 13% ear drops | Provider notes
|
| 01.01.01 | Aluminium hydroxide Alu-Cap® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 09.05.02.02 | Aluminium Hydroxide Alu-Cap® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
|
| 01.01.01 | Aluminium hydroxide + Magnesium hydroxide + Simeticone Maalox Plus® | Provider notes
|
| 04.09.01 | Amantadine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 05.03.04 | Amantadine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 14.04 | Ambirix® Hepatitis A vaccine with Hepatitis B vaccine | Provider notes
|
| 02.05.01 | Ambrisentan | Provider notes
|
| 11.03.01 | Amikacin 0.4mg/0.1mL intravitreal pack | Provider notes
|
| 11.03.01 | Amikacin 1.5% eye drops | Provider notes
|
| 24.01 | Amikacin 2.5% eye drops |
MEH: Bacterial & Mycobacteria keratitis |
| 05.01.04 | Amikacin injection | Provider notes
|
| 02.02.03 | Amiloride Hydrochloride | Provider notes
|
| 13.08 | Aminolevulinic acid | Secondary care notes
|
| 03.01.03 | Aminophylline Phyllocontin Continus® | Provider notes
|
| 03.01.03 | Aminophylline IV | Provider notes
|
| 05.01.09 | Aminosalicylic acid | Provider notes
|
| 02.03.02 | Amiodarone | Provider notes
|
| 04.02.01 | Amisulpride | Provider notes
|
| 04.03.01 | Amitriptyline | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.07.03 | Amitriptyline | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.07.04.02 | Amitriptyline | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 02.06.02 | Amlodipine | Provider notes
|
| 13.10.02 | Amorolfine 5% nail lacquer | Provider notes
|
| 05.01.01.03 | Amoxicillin | Provider notes
|
| 11.03.02 | Amphotericin 0.15% eye drops | Provider notes
|
| 11.03.02 | Amphotericin 5mcg/0.1ml intravitreal injection | Provider notes
|
| 05.02 | Amphotericin infusion Fungizone® | Provider notes
|
| 05.02 | Amphotericin liposomal infusion AmBisome® | Provider notes
|
| 09.01.04 | Anagrelide | Provider notes
|
| 10.01.03 | Anakinra | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for adult-onset Stills disease in line with NHSE commissioning policy (JFC October 2018) Provider notes
|
| 10.04 | Anakinra | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for secondary haemophagocytic lymphohistiocytosis subject to individual funding approval (JFC September 2018). Additional information: Evidence to support SC or IV (local practice is to administer in 100mL sodium chloride 0.9%w/v over 1 hour). Provider notes
|
| 10.04 | Anakinra | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for gout for patients who are hospitalised and refractory to all other treatments. The usual dose is 100 mg daily subcutaneously for 3 days (JFC September 2014) Provider notes
|
| 20 | Anakinra | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | Anakinra | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.03.04.01 | Anastrozole | Provider notes
|
| 05.02.04 | Anidulafungin | Approved for invasive candidiasis, subject to local Antimicrobial Committee approval (JFC February 2019). Provider notes
|
| 12.03.01 | Antacid + Oxetacaine oral suspension | Approved for oral mucositis post radiotherapy (JFC February 2019). Provider notes
|
| 11.04.02 | Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin® | Provider notes
|
| 14.05.03 | Anti-D (Rh0) Immunoglobulin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 02.11 | Antithrombin III Kybemin® | Provider notes
|
| 08.02.02 | Antithymocyte immunoglobulin - rabbit Thymoglobuline® | Provider notes
|
| 01.07.02 | Anusol-HC® | Provider notes
|
| 02.08.02 | Apixaban | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. See NICE TA for eligibity criteria Provider notes
|
| 02.08.02 | Apixaban | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for (JFC January 2019):
Dose is 2.5mg twice-daily.
Provider notes
|
| 04.09.01 | Apomorphine | Provider notes
|
| 11.08.02 | Apraclonidine ophthalmic solution Iopidine® | Provider notes
|
| 10.01.03 | Apremilast | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for:
Provider notes
|
| 13.05.03 | Apremilast | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.06 | Aprepitant | Provider notes
|
| A5.02.04 | Aquacel | Provider notes
|
| 13.02.01 | Aquadrate® cream Urea 10% | Provider notes
|
| 13.02.01.01 | Aqueous Cream BP | Provider notes
|
| 01.06.03 | Arachis Oil Enema | Provider notes
|
| 02.08.01 | Argatroban | Anticoagulation in adult patients with heparin-induced thrombocytopenia (HIT) type II who require parenteral antithrombotic therapy and have renal failure (February 2013) Provider notes
|
| 06.05.02 | Argipressin | Provider notes
|
| 04.02.01 | Aripiprazole | Intramuscular formulation (7.5mg/1mL) is approved for the rapid control of agitation and disturbed behaviours in adult patients with schizophrenia or with manic episodes in Bipolar I Disorder when oral therapy is not appropriate and where IM haloperidol is not recommended. (JFC January 2019) Provider notes
|
| 05.04.01 | Artemether + Lumefantrine | Provider notes
|
| 20 | Artesunate | Approved for severe falciparum malaria (November 2015) Provider notes
|
| 15.02 | Articaine hydrochloride + Adrenaline injection | Provider notes
|
| 07.04.03 | Ascorbic Acid Vitamin C | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 09.06.03 | Ascorbic Acid Vitamin C | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| A5.03.03 | Askina Calgitrol | Provider notes
|
| 02.09 | Aspirin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.07.01 | Aspirin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 05.03.01 | Atazanavir | Provider notes
|
| 05.03.01 | Atazanavir + cobicistat Evotaz® | Provider notes
|
| 02.04 | Atenolol | Provider notes
|
| 08.01.05 | Atezolizumab | Provider notes
|
| 04.04 | Atomoxetine | Provider notes
|
| 02.12 | Atorvastatin | Provider notes
|
| 07.01.03 | Atosiban | Provider notes
|
| 05.04.08 | Atovaquone | Provider notes
|
| 05.04.01 | Atovaquone + Proguanil | Provider notes
|
| 15.01.05 | Atracurium besilate | Provider notes
|
| A5.01.01 | Atrauman | Provider notes
|
| A5.03.03 | Atrauman AG | Provider notes
|
| 11.05 | Atropine eye drops | Provider notes
|
| 11.05 | Atropine eye drops - single use | Provider notes
|
| 15.01.03 | Atropine injection | Provider notes
|
| 15.01.03 | Atropine Minijet® injection | Provider notes
|
| 01.02 | Atropine tabs | Provider notes
|
| 14.04 | Avaxim® Hepatitis A vaccine Single Component | Provider notes
|
| 13.02.01.01 | Aveeno® Bath Oil |
#Secondary care notes
|
| 13.02.01 | Aveeno® cream | Provider notes
|
| 08.01.05 | Avelumab | Provider notes
|
| 07.04.05 | Aviptadil + phentolamine Invicorp® | Erectile dysfunction in men who have failed to respond to oral PDE5i (sildenafil and tadalafil) and intracavernosal/urethral alprostadil. Secondary care initiation, primary care continuation (SLS only) (JFC November 2017) Provider notes
|
| 08.01.05 | Axitinib | See NICE TA for eligibility criteria Provider notes
|
| A2.02.02.01 | AYMES Complete |
Provider notes Non-formulary
Primary care notes Second-choice product - for patients who did not tolerate first-line choices - see Primary Care Guidance |
| A2.02.01.02 | AYMES Shake |
Provider notes Non-formulary
Primary care notes First-choice product - see Primary Care Guidance |
| A2.02.02.03 | AYMES Shake Compact |
Provider notes Non-formulary
Primary care notes First-choice product for patients who cannot tolerate 200mL presentation - see Primary Care Guidance |
| 08.01.03 | Azacitidine | See NICE TA for eligibility criteria Provider notes
|
| 01.05.03 | Azathioprine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 01.05.03 | Azathioprine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for autoimmune hepatitis (JFC February 2018) Provider notes
|
| 08.02.01 | Azathioprine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 10.01.03 | Azathioprine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 13.05.03 | Azathioprine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 13.05.03 | Azathioprine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for Pemphigus Vulgaris (PV), Mucous membrane pemphigoid (MMP), Recurrent apthous stomatitis (RAS), Oral lichen planus (OLP), Oral Crohn’s disease (OCD) (JFC June 2017) Provider notes
|
| 13.06.01 | Azelaic acid 15% gel Finacea® | Provider notes
|
| 13.06.01 | Azelaic acid 20% cream Skinoren® | Provider notes
|
| 12.02.01 | Azelastine + Fluticasone nasal spray Dymista® | Approved for allergic rhinitis when 1st line betamethasone monotherapy and 2nd line fluticasone monotherapy have failed (JFC September 2015) Provider notes
|
| 11.04.02 | Azelastine 0.5 mg/ml eye drops | Provider notes
|
| 12.02.01 | Azelastine nasal spray Rhinolast® | Provider notes
|
| 11.03.01 | Azithromycin 15 mg/g eye drops | Provider notes
|
| 05.01.05 | Azithromycin tabs/caps/suspension | Provider notes
|
| 24.01 | Azithromyin 1.5% single use eye drops | MEH: Ocular Chlamydia infections; blepharitis |
| 05.01.02.03 | Aztreonam | Provider notes
|
| 10.02.02 | Baclofen Intrathecal | Provider notes
|
| 10.02.02 | Baclofen oral | Provider notes
|
| 13.02.01.01 | Balneum® bath oil |
Provider notes
|
| 13.02.01 | Balneum® cream Urea 5% | Provider notes
|
| 13.02.01.01 | Balneum® Plus bath oil | Provider notes
|
| 13.02.01 | Balneum® Plus cream Urea 5% | Provider notes
|
| 10.01.03 | Baricitinib | Approved for:
Provider notes
|
| 08.02.02 | Basiliximab | See NICE TA for eligibility criteria Provider notes
|
| 08.02.04 | BCG bladder instillation ImmuCyst® | Provider notes
|
| 08.02.04 | BCG bladder instillation OncoTICE® | Provider notes
|
| 14.04 | BCG diagnostic agent - Intradermal injection | Provider notes
|
| 14.04 | BCG vaccine - Intradermal injection | Provider notes
|
| 12.02.01 | Beclometasone dipropionate 50mcg/spray nasal spray | Provider notes
|
| 03.02 | Beclometasone dipropionate inhaler (pMDI) Clenil Modulite® | Provider notes
|
| 03.02 | Beclometasone dipropionate inhaler (pMDI) Qvar® | Provider notes
|
| 03.02 | Beclometasone diproponate + Formoterol + Glycopyrronium inhaler (pMDI) Trimbow® | Approved for COPD when ICS + LAMA + LABA inhalation therapy is indicated, as per NICE guidance (JFC September 2019) Provider notes
|
| 03.02 | Beclometasone diproponate + Formoterol inhaler (pMDI) Fostair® | Provider notes
|
| 05.01.09 | Bedaquiline | Approved for XDR-TB and MDR-TB in line with the NHS England Clinical Commissioning Policy F04/P/a (JFC April 2017) Provider notes
|
| 03.04.02 | Bee and Wasp Allergen Extracts Pharmalgen® | Provider notes
|
| 10.01 | Belimumab | Provider notes
|
| 08.01.01 | Bendamustine | See NICE TA for eligibility criteria Provider notes
|
| 02.02.01 | Bendroflumethiazide | Provider notes
|
| 04.02.01 | Benperidol | Provider notes
|
| 13.09 | Benzalkonium chloride 0.5% shampoo Dermax® | Provider notes
|
| 20 | Benzathine benzylpenicillin | Provider notes
|
| 10.04 | Benzbromarone | Provider notes
|
| 13.10.02 | Benzoic Acid Ointment, Compound BP Whitfield's ointment | Provider notes
|
| 13.06.01 | Benzoyl peroxide - Topical PanOxyl® |
Provider notes
|
| 13.06.01 | Benzoyl peroxide 5% + Clindamycin 1% gel Duac® Once Daily | Provider notes
|
| 12.03.01 | Benzydamine Difflam® | Provider notes
|
| 13.10.04 | Benzyl Benzoate Application BP 25% | Provider notes
|
| 05.01.01.01 | Benzylpenicillin | Provider notes
|
| 04.06 | Betahistine Dihydrochloride | Provider notes
|
| 10.01.02.02 | Betamethasone | Provider notes
|
| 13.04 | Betamethasone dipropionate 0.05% - Topical Diprosone® | Provider notes
|
| 13.04 | Betamethasone dipropionate 0.05% + Salicylic acid 3% - Topical Diprosalic® | Provider notes
|
| 13.04 | Betamethasone dipropionate 0.064% + Clotrimazole 1% - Topical Lotriderm® | Provider notes
|
| 11.04.01 | Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 12.01.01 | Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 12.02.03 | Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 12.01.01 | Betamethasone sodium phosphate 0.1% drops | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 12.02.01 | Betamethasone sodium phosphate 0.1% drops | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 11.04.01 | Betamethasone sodium phosphate 0.1% drops, 0.1% ointment | Provider notes
|
| 12.03.01 | Betamethasone soluble tablets | Approved for oral mucosal inflammatory disease (JFC March 2018) Provider notes
|
| 06.03.02 | Betamethasone systemic injection | Provider notes
|
| 06.03.02 | Betamethasone tablets | Provider notes
|
| 13.04 | Betamethasone valerate 0.025% - Topical Betnovate-RD® | Provider notes
|
| 13.04 | Betamethasone valerate 0.1% - Topical | Provider notes
|
| 13.04 | Betamethasone valerate 0.1% + Clioquinol 3% - Topical | Provider notes
|
| 13.04 | Betamethasone valerate 0.1% + Fucidic acid 2% - Topical Fucibet® | Provider notes
|
| 13.04 | Betamethasone valerate 0.1% + Neomycin 0.5% - Topical | Provider notes
|
| 13.04 | Betamethasone valerate 0.1% scalp application Betacap® | Provider notes
|
| 13.04 | Betamethasone valerate 0.12% scalp application Bettamousse® | Provider notes
|
| 11.06 | Betaxolol 0.5% solution eye drops | See NCL guideline for place in therapy. Provider notes
|
| 08.01.05 | Bevacizumab | Provider notes
|
| 11.08.02 | Bevacizumab intravitreal injection | Approved for:
Provider notes
|
| 14.04 | Bexsero® Meningococcal group B Vaccine | Approved in line with Public Health England Men B immunisation programme (JFC August 2015) Provider notes
|
| 02.12 | Bezafibrate | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.03.04.02 | Bicalutamide | Provider notes
|
| 11.06 | Bimatoprost 0.01% eye drops | See NCL guideline for place in therapy. Provider notes
|
| 11.06 | Bimatoprost 0.03% + Timolol 0.1% eye drops Ganfort® | Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy. Provider notes
|
| 11.06 | Bimatoprost 0.03% + Timolol 0.1% eye drops - preservative free Ganfort® | Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. See NCL guideline for place in therapy. Combination therapies to be used when compliance/cost issues arise. See NCL guideline for place in therapy. Provider notes
|
| 11.06 | Bimatoprost 0.03% eye drops- single use | See NCL guideline for place in therapy. Provider notes
|
| 08.01.05 | Binimetinib tabs | See NICE TA for eligibility criteria Provider notes
|
| 09.08.01 | Biotin | Provider notes
|
| 12.03.05 | BioXtra® oral gel | Provider notes
|
| 06.01.01.02 | Biphasic Insulin Aspart NovoMix® 30 | Provider notes
|
| 06.01.01.02 | Biphasic Insulin Lispro Humalog® Mix25, Humalog® Mix50 | Approved for:
Provider notes
|
| 06.01.01.02 | Biphasic Isophane Insulin Humulin® M3 | Provider notes
|
| 06.01.01.02 | Biphasic Isophane Insulin Insuman® Comb 25, Insuman® Comb 50 | First choice biphasic human insulin. See NCL guideline for insulin in Type 2 diabetes guideline. Insuman® Comb 15 removed from the market (January 2020) Provider notes
|
| 01.06.02 | Bisacodyl | Provider notes
|
| 01.03.03 | Bismuth subsalicylate Pepto-Bismol® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for eradication of H.Pylori, after first-line treatment and previous exposure to levofloxacin (JFC April 2019). Provider notes
|
| 02.04 | Bisoprolol | Provider notes
|
| 02.08.01 | Bivalirudin | Provider notes
|
| 08.01.02 | Bleomycin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 14.04 | Boostrix-IPV | Provider notes
|
| 08.01.05 | Bortezomib injection | See NICE TA for eligibility criteria Provider notes
|
| 02.05.01 | Bosentan | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for digital ulceration in systemic sclerosis in line with NHSE Clinical Commissioning Policy A13/P/e (May 2015) Provider notes
|
| 02.05.01 | Bosentan | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.01.05 | Bosutinib | See NICE TA for eligibility criteria Provider notes
|
| 01.07.04 | Botulinum toxin type A Botox®, Dysport®, Xeomin® | NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.07.04.02 | Botulinum Toxin Type A Botox® | NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.09.03 | Botulinum Toxin Type A Botox®, Dysport®, Xeomin® | NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. Provider notes
|
| 07.04.02 | Botulinum toxin Type A Botox® | NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. Approved for neurogenic bladder dysfunction for patients refractory to oral therapies (JFC January 2013) QUERY FUNDING
Provider notes
|
| 13.12 | Botulinum toxin type A | NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | Botulinum toxin Type A Botox®, Dysport®, Xeomin® | NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. Approved for Sphincter of Oddi Dysfunction (JFC January 2013). QUERY funding Provider notes
|
| 04.09.03 | Botulinum Toxin Type B NeuroBloc® | Provider notes
|
| 08.01.05 | Brentuximab vedotin | See NICE TA for eligibility criteria Provider notes
|
| 08.01.05 | Brigatinib tabs | See NICE TA for eligibility criteria Provider notes
|
| 11.06 | Brimonidine 0.2% + Timolol 0.5% eye drops Combigan® | Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy. Provider notes
|
| 11.06 | Brimonidine 0.2% eye drops | See NCL guideline for place in therapy. Provider notes
|
| 13.06.01 | Brimonidine 3 mg/g gel | Approved for moderate to severe rosacea causing psychological distress or reduced quality of life - initiation by secondary care Dermatologist and continuation in primary care (JFC September 2014) Provider notes
|
| 11.06 | Brinzolamide 0.1% eye drops | See NCL guideline for place in therapy. Provider notes
|
| 11.06 | Brinzolamide 1% + Timolol 0.5% eye drops Azarga® | Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy. Provider notes
|
| 13.05.03 | Brodalumab | Provider notes
|
| 04.09.01 | Bromocriptine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 06.07.01 | Bromocriptine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 01.05.02 | Budesonide Entocort® | Provider notes
|
| 01.05.02 | Budesonide Budenofalk® | Budenofalk® 2mg/dose rectal foam approved for active ulcerative colitis limited to the rectum and sigmoid colon as second-line (prednisolone retention enema is the first-line choice) (JFC October 2018). Provider notes
|
| 03.02 | Budesonide + Formoterol inhaler (DPI) Symbicort® Turbohaler, DuoResp Spiromax® | Not approved as the sole inhaler for asthma (SMART), may be used twice daily for asthma (JFC September 2015). Provider notes
|
| 12.02.01 | Budesonide 100mcg/spray nasal spray | Provider notes
|
| 03.02 | Budesonide inhaler (DPI) Pulmicort® Turbohaler | Provider notes
|
| 03.02 | Budesonide nebuliser suspension | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | Budesonide nebuliser suspension | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved as second-line choice (after fluticasone inhaler) for eosinophilic oesophagitis in both adults and children. Dose should be dispersed in viscous suspending agent (e.g. Splenda slurry). Starting dose is 1 mg twice-daily for adults and children > 10 years old, 1 mg once-daily for children < 10 years old; down titrate dose for maintenance dosing (JFC February 2018) Provider notes
|
| 02.02.02 | Bumetanide | Provider notes
|
| 15.02 | Bupivacaine | Approved for post-operative pain management following limb amputation for peripheral arterial disease to reduce post-operative opioid requirement (0.125% infusion via perineural stump catheter) (JFC September 2019). Provider notes
|
| 15.02 | Bupivacaine + Adrenaline | Provider notes
|
| 15.02 | Bupivacaine + Fentanyl | Provider notes
|
| 15.02 | Bupivacaine + Glucose Marcain Heavy® | Provider notes
|
| 04.07.02 | Buprenorphine patch '35', '52.5','70' | Provider notes
|
| 04.07.02 | Buprenorphine patch '5' and '10' | Only buprenorphine patch ‘5’ and ‘10’ patches are available. Restricted for patients unable to take oral opioids due to swallowing difficulties / short bowel AND requiring a lower dose transdermal opioid dose than the 12 micrograms fentanyl patch (JFC March 2015). Provider notes
|
| 04.07.02 | Buprenorphine sublingual tablets | Provider notes
|
| 04.10.03 | Buprenorphine sublingual tablets | Provider notes
|
| 04.10.02 | Bupropion | Provider notes
|
| 06.07.02 | Buserelin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 06.07.02 | Buserelin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.03.04.02 | Buserelin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.01.02 | Buspirone | Provider notes
|
| 08.01.01 | Busulfan infusion | Provider notes
|
| 08.01.01 | Busulfan tablets | Provider notes
|
| 03.04.03 | C1 Esterase Inhibitor Berinert® | Provider notes
|
| 08.01.05 | Cabazitaxel | See NICE TA for eligibility criteria Provider notes
|
| 04.09.01 | Cabergoline | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 06.07.01 | Cabergoline | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.01.05 | Cabozantinib caps Cometriq® | See NICE TA for eligibility criteria Provider notes
|
| 08.01.05 | Cabozantinib tabs Cabometyx® | See NICE TA for eligibility criteria Provider notes
|
| 21.01 | Cacicol | Non-healing corneal ulcers/ persistent epithelial defects. |
| 13.03 | Calamine lotion | Provider notes
|
| 13.05.02 | Calcipotriol 50mcg/g - Topical Dovonex® | Provider notes
|
| 13.05.02 | Calcipotriol 50micrograms/g + Betamethasone dipropionate 0.05% - Topical Dovobet® | Provider notes
|
| 13.05.02 | Calcipotriol 50micrograms/g + Betamethasone dipropionate 0.05% - Topical foam Enstilar® |
Approved after failure of combined topical steroid + vitamin D2 (e.g. Dovobet ointment) (JFC May 2017) Provider notes
|
| 06.06.01 | Calcitonin (salmon) | Provider notes
|
| 13.05.02 | Calcitriol 3mcg/g - Topical Silkis® | Provider notes
|
| 09.05.01.02 | Calcitriol injection | Provider notes
|
| 09.06.04 | Calcitriol oral | Provider notes
|
| 09.05.02.02 | Calcium Acetate Phosex® | Provider notes
|
| 09.06.04 | Calcium and Ergocalciferol | Provider notes
|
| 09.05.01.01 | Calcium carbonate Cacit® | Provider notes
|
| 09.05.01.01 | Calcium carbonate Calcichew® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 09.05.01.01 | Calcium Carbonate Adcal® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 09.05.02.02 | Calcium Carbonate Calcichew® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 09.05.02.02 | Calcium Carbonate Adcal® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 09.05.02.02 | Calcium Carbonate Calcium-500® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 09.05.01.01 | Calcium Chloride injection | Provider notes
|
| 08.01 | Calcium Folinate | Provider notes
|
| 09.05.01.01 | Calcium Gluconate 10% injection | Provider notes
|
| 09.05.01.01 | Calcium Gluconate effervescent tablets | Provider notes
|
| 13.02.01 | Calmurid® cream Urea 10% | Provider notes
|
| A2.04.01.02 | Calogen | Provider notes
|
| 06.01.02.03 | Canagliflozin | Provider notes
|
| 08.02.04 | Canakinumab | Provider notes
|
| 02.05.05.02 | Candesartan | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 02.09 | Cangrelor | Provider notes
|
| 08.01.03 | Capecitabine | See NICE TA for eligibility criteria Provider notes
|
| 05.01.09 | Capreomycin | Provider notes
|
| 10.03.02 | Capsaicin cream | Provider notes
|
| 10.03.02 | Capsaicin patch | JFC approved for neuropathic pain (January 2013) Provider notes
|
| 02.05.05.01 | Captopril | Provider notes
|
| 04.02.03 | Carbamazepine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.07.03 | Carbamazepine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.08.01 | Carbamazepine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Prescribe by brand when used for epilepsy. Immediate release and modified release. Provider notes
|
| 07.01.01 | Carbetocin | Provider notes
|
| 06.02.02 | Carbimazole | Provider notes
|
| 03.07 | Carbocisteine | Provider notes
|
| 11.08.01 | Carbomers eye gel Viscotears®, GelTears® and others | Provider notes
|
| 08.01.05 | Carboplatin | Provider notes
|
| 08.01.05 | Carboplatin + paclitaxel | Approved as first-line treatment for advanced squamous cell carcinoma of anus (JFC March 2019). Note: Carboplatin AUC5 day 1 of 28 day cycles + paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of 28 day cycles. 6 cycles (each cycle 28 days) Provider notes
|
| 08.01.05 | Carboplatin + paclitaxel (CROSS) | Approved as neo-adjuvant treatment before surgery for adenocarcinoma of the oesophagus or the gastro-oesophageal junction (JFC November 2017) Provider notes
|
| 07.01.01 | Carboprost | Provider notes
|
| 08.01.05 | Carfilzomib | See NICE TA for eligibility criteria Provider notes
|
| 11.08.01 | Carmellose eye drops - single use | Provider notes
|
| 12.03.01 | Carmellose Sodium Orabase® | Provider notes
|
| 02.04 | Carvedilol | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | Carvedilol | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for primary and secondary prevention of variceal bleeding for patients who do not respond to or cannot tolerate propranolol (August 2015) Provider notes
|
| 05.02.04 | Caspofungin | Provider notes
|
| A5.02.05 | Cavi-Care | Provider notes
|
| 05.01.02.01 | Cefalexin | Provider notes
|
| 05.01.02.01 | Cefazolin | Provider notes
|
| 05.01.02.01 | Cefixime | Provider notes
|
| 05.01.02.01 | Cefotaxime | Provider notes
|
| 05.01.02.01 | Ceftazidime | Provider notes
|
| 05.01.02.01 | Ceftazidime + Avibactam | Approved for the treatment of infections caused by non-MBL carbapenemase-producing aerobic Gram-negative organisms, that have proven susceptibly to ceftazidime-avibactam and where the only alternative active agents, if any, are limited to colistin, tigecycline and fosfomycin, which cannot be used due to resistance or intolerance - Microbiology recommendation only (JFC August 2017) Provider notes
|
| 11.03.01 | Ceftazidime 5% eye drops | Provider notes
|
| 05.01.02.01 | Ceftolozane + tazobactam | Approved for multi-resistant Gram-negative organisms that have proven susceptibly to ceftolozane-tazobactam and where the only alternative active agents, if any, are limited to colistin, tigecycline and fosfomycin (JFC September 2016) Provider notes
|
| 05.01.02.01 | Ceftriaxone | Provider notes
|
| 05.01.02.01 | Cefuroxime | Provider notes
|
| 11.03.01 | Cefuroxime 5% eye drops | Provider notes
|
| 11.03.01 | Cefuroxime intracameral injection Aprokam® | Approved for prophylaxis post-cataract surgery (June 2013) Provider notes
|
| 10.01.01 | Celecoxib | Provider notes
|
| 20 | Celiprolol | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for vascular Ehlers-Danlos syndrome (JFC April 2016) Provider notes
|
| 08.01.05 | Ceritinib | Provider notes
|
| 10.01.03 | Certolizumab pegol | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for:
Provider notes
|
| 13.05.03 | Certolizumab pegol | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. See NICE TA for eligibility criteria Provider notes
|
| 03.04.01 | Cetirizine | Provider notes
|
| 13.02.01.01 | Cetraben® bath additive |
Provider notes
|
| 13.02.01 | Cetraben® cream | Cetraben cream, Enopen cream, ExCetra cream, Exmaben cream and Soffen cream all contain Liquid paraffin light 105 mg/g + White soft paraffin 132 mg/g. Provider notes
|
| 13.09 | Cetrimide 10% + Undecenoic acid 1% shampoo Ceanel Concentrate® | Provider notes
|
| 08.01.05 | Cetuximab | See NICE TA for eligibility criteria Provider notes
|
| 04.01.01 | Chloral Hydrate | Provider notes
|
| 08.01.01 | Chlorambucil | Provider notes
|
| 05.01.07 | Chloramphenicol | Provider notes
|
| 11.03.01 | Chloramphenicol 0.5% eye drops - Single use drops | Provider notes
|
| 11.03.01 | Chloramphenicol 0.5% eye drops, 1% eye ointment | Provider notes
|
| 12.01.01 | Chloramphenicol 5% ear drops | Provider notes
|
| 04.01.02 | Chlordiazepoxide | Provider notes
|
| 11.03.01 | Chlorhexidine | Provider notes
|
| 13.11.02 | Chlorhexidine + Alcohol wipes Clinell Alcoholic 2% Chlorhexidine Wipes® | Provider notes
|
| 13.11.02 | Chlorhexidine 0.015% + Cetrimide 0.15% skin cleaner Tisept® | Provider notes
|
| 12.02.03 | Chlorhexidine 0.1% + Neomycin 0.5% cream Naseptin® | Provider notes
|
| 12.03.04 | Chlorhexidine 0.2% mouthwash | Provider notes
|
| 12.03.04 | Chlorhexidine 0.2% oral spray | Provider notes
|
| 12.03.04 | Chlorhexidine 1% dental gel | Provider notes
|
| 07.04.04 | Chlorhexidine acetate 0.02% catheter maintenance solution | Provider notes
|
| 13.11.02 | Chlorhexidine skin cleaners | Provider notes
|
| 12.01.03 | Chlorobutanol 5% + Arachis (peanut) oil ear drops Cerumol® | Provider notes
|
| 15.02 | Chloroprocaine | Provider notes
|
| 05.04.01 | Chloroquine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 10.01.03 | Chloroquine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | Chlorothiazide | Provider notes
|
| 03.04.01 | Chlorphenamine | Provider notes
|
| 04.02.01 | Chlorpromazine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.06 | Chlorpromazine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 12.03.01 | Choline Salicylate 8.7% oral gel Bonjela® Adult, Teejel® | Provider notes
|
| 06.05.01 | Chorionic Gonadotrophin Choragon®, Pregnyl® | Provider notes
|
| 01.05.03 | Ciclosporin | NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.02.02 | Ciclosporin Capsorin® | NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.02.02 | Ciclosporin Deximune® | NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.02.02 | Ciclosporin Neoral® | NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.02.02 | Ciclosporin Capimune® | NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.02.02 | Ciclosporin Sandimmun® | NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. Provider notes
|
| 10.01.03 | Ciclosporin | NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. Provider notes
|
| 13.05.03 | Ciclosporin | NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. Approved for:
Provider notes
|
| 11.99.99.99 | Ciclosporin 0.06% eye drops | Provider notes
|
| 11.99.99.99 | Ciclosporin 0.1% eye drops Ikervis® | Approved for ocular inflammatory conditions. See NCL fact sheet.
Provider notes
|
| 11.99.99.99 | Ciclosporin 0.2% eye ointment | Approved for ocular inflammatory conditions. See NCL fact sheet.
Provider notes
|
| 11.99.99.99 | Ciclosporin 2% eye drops | Provider notes
|
| 01.03.01 | Cimetidine | Provider notes
|
| 09.05.01.02 | Cinacalcet | Approved for complex primary hyperparathyroidism in adults in line with NHSE clinical commissioning policy (JFC April 2018) Provider notes
|
| 04.06 | Cinnarizine | Provider notes
|
| 02.12 | Ciprofibrate | Provider notes
|
| 05.01.12 | Ciprofloxacin | Provider notes
|
| 11.03.01 | Ciprofloxacin 0.3% eye drops/ointment | Provider notes
|
| 15.01.05 | Cisatracurium | Provider notes
|
| 08.01.05 | Cisplatin | Provider notes
|
| 04.03.03 | Citalopram | Provider notes
|
| 08.01.03 | Cladribine injection | Provider notes
|
| 08.02.04 | Cladribine tablets Mavenclad® | Provider notes
|
| 05.01.05 | Clarithromycin | Provider notes
|
| 05.01.06 | Clindamycin | Provider notes
|
| 13.06.01 | Clindamycin 1% topical solution Dalacin T® | Provider notes
|
| 07.02.02 | Clindamycin 2% vaginal cream Dalacin® | Provider notes
|
| 04.08.01 | Clobazam | Provider notes
|
| 13.04 | Clobetasol propionate + Neomycin + Nystatin - Topical | Provider notes
|
| 13.04 | Clobetasol propionate 0.05% - Topical Dermovate® | Provider notes
|
| 13.04 | Clobetasol propionate 0.05% shampoo Etrivex® | Provider notes
|
| 20 | Clobetasol propionate 1 in 4 in White Soft Paraffin | Provider notes
|
| 13.04 | Clobetasone butyrate 0.05% - Topical Eumovate® | Provider notes
|
| 13.04 | Clobetasone butyrate 0.05% + Oxytetracyline 3% + Nystatin - Topical Trimovate® | Provider notes
|
| 05.01.10 | Clofazimine | Provider notes
|
| 04.01.01 | Clomethiazole | Provider notes
|
| 06.05.01 | Clomifene | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
|
| 04.03.01 | Clomipramine Antidepressant | Provider notes
|
| 04.02.03 | Clonazepam | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.07.03 | Clonazepam | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.08.01 | Clonazepam | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 02.05.02 | Clonidine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.07.04.02 | Clonidine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | Clonidine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 02.09 | Clopidogrel | See NICE TA for eligibility Provider notes
|
| 07.02.02 | Clotrimazole | Provider notes
|
| 13.10.02 | Clotrimazole 1% - Topical | Provider notes
|
| 12.01.01 | Clotrimazole 1% ear drops | Provider notes
|
| 11.03.02 | Clotrimazole 1% eye drops | Provider notes
|
| 04.02.01 | Clozapine Clozaril® | Provider notes
|
| 21.01 | Co‐careldopa | Rotigotine or co‐careldopa for Hemispatial neglect that is interfering with progress of neurorehabilitation - UCLH only |
| 13.09 | Coal tar 1% + Coconut oil 1% + Salicylic acid 0.5% shampoo Capasal® | Provider notes
|
| 13.05.02 | Coal tar 12% + Salicylic acid 2% + Precipitated sulfur 4% scalp ointment Cocois® | Provider notes
|
| 13.05.02 | Coal tar 12% + Salicylic acid 2% + Precipitated sulfur 4% scalp ointment Sebco® | Provider notes
|
| 13.05.02 | Coal tar and salicylic acid ointment, BP | Provider notes
|
| 13.09 | Coal tar extract 5% alcoholic shampoo Alphosyl 2 in 1® | Provider notes
|
| 20 | Coal tar in Betamethasone ointment | Provider notes
|
| 13.05.02 | Coal tar lotion 5% Exorex® | Provider notes
|
| 02.02.04 | Co-amilofruse | Provider notes
|
| 02.02.04 | Co-amilozide | Provider notes
|
| 05.01.01.03 | Co-Amoxiclav | Provider notes
|
| 04.09.01 | Co-Beneldopa immediate release | Provider notes
|
| 04.09.01 | Co-Beneldopa modified release | Provider notes
|
| 05.03.01 | Cobicistat | Second line protease inhibitor booster for HIV for confirmed ritonavir intolerance (March 2016) Provider notes
|
| 08.02.04 | Cobimetinib | Provider notes
|
| 11.07 | Cocaine 10% eye drops | Provider notes
|
| 11.07 | Cocaine 4% eye drops | Provider notes
|
| 04.07.02 | Cocaine Hydrochloride Solution 10% w/v | Provider notes
|
| 15.02 | Cocaine mouthwash | Provider notes
|
| 04.09.01 | Co-Careldopa + Entacapone | Provider notes
|
| 04.09.01 | Co-Careldopa immediate release | Provider notes
|
| 04.09.01 | Co-Careldopa intestinal gel Duodopa® | Approved for Parkinson's disease in line with NHSE clinical commissioning policy D04/P/e (JFC November 2019). Provider notes
|
| 04.09.01 | Co-Careldopa modified release | Provider notes
|
| 04.07.01 | Co-codamol 30/500 Paracetamol + Codeine | Provider notes
|
| 04.07.01 | Co-codamol 8/500 Paracetamol + Codeine | Provider notes
|
| 13.06.02 | Co-Cyprindiol 2000/35 (cyproterone 2mg / ethinylestradiol 35micrograms) Dianette® | Provider notes
|
| 01.06.02 | Co-danthramer | Provider notes
|
| 01.06.02 | Co-danthrusate | Provider notes
|
| 01.04.02 | Codeine | NOTE: There is more than one monograph for codeine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.07.02 | Codeine | NOTE: There is more than one monograph for codeine, click here to search for formulary status and its use for other indications. Provider notes
|
| 03.09.01 | Codeine Linctus BP | NOTE: There is more than one monograph for codeine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.07.01 | Co-dydramol 10/500 Paracetamol + Dihydrocodeine | Provider notes
|
| 10.01.04 | Colchicine | Provider notes
|
| 20 | Colchicine | Approved for oral mucosal inflammatory disease in particular ‘Recurrent apthous stomatitis (RAS)’ and ‘Oral ulceration in Behcet’s disease’ (JFC April 2018). Additional information: Transfer of care to GPs after stabilisation in secondary care. Monitoring requirements to be communicated to the GP via letter. Monitoring requirements are FBC, U&E and LFTs at 3 months, 6 months and then annually, CK only if myalgia. Provider notes
|
| 09.06.04 | Colecalciferol + Calcium carbonate Adcal-D3® | Provider notes
|
| 09.06.04 | Colecalciferol caps/liquid | Provider notes
|
| 02.12 | Colesevelam Cholestagel® | Provider notes
|
| 02.12 | Colestipol Colestid® | Provider notes
|
| 01.09.02 | Colestyramine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 02.12 | Colestyramine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 05.01.07 | Colistimethate for nebulisation | Provider notes
|
| 05.01.07 | Colistimethate injection | Provider notes
|
| 13.10.05 | Collodion Flexible BP | Provider notes
|
| 01.01.01 | Co-magaldrox | Provider notes
|
| 09.02.02.01 | Compound Sodium Lactate (Hartmann's) Intravenous Infusion | Provider notes
|
| 03.04.03 | Conestat Alfa | Approved for prophylaxis and treatment of hereditary angioedema in line with NHS Commissioning Policies (JFC October 2018) Provider notes
|
| 06.04.01.01 | Conjugated oestrogen Premarin® | Provider notes
|
| 06.04.01.01 | Conjugated oestrogen with Medroxyprogesterone Premique® | Provider notes
|
| 01.04.02 | Co-Phenotrope | Provider notes
|
| 02.04 | Co-tenidone | Provider notes
|
| 05.01.08 | Co-trimoxazole | Provider notes
|
| A2.03.01 | Cow and Gate Pepti-Junior | Provider notes
|
| 08.01.05 | Crisantaspase | Provider notes
|
| 08.01.05 | Crizotinib | See NICE TA for eligibility criteria Provider notes
|
| 13.03 | Crotamiton 10% cream Eurax® | Provider notes
|
| 09.01.02 | Cyanocobalamin | Provider notes
|
| 04.06 | Cyclizine | Provider notes
|
| 11.05 | Cyclopentolate eye drops | Provider notes
|
| 11.05 | Cyclopentolate eye drops - single use | Provider notes
|
| 08.01.01 | Cyclophosphamide | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 10.01.03 | Cyclophosphamide | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
|
| 05.01.09 | Cycloserine | Provider notes
|
| 03.04.01 | Cyproheptadine | Provider notes
|
| 06.04.02 | Cyproterone | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.03.04.02 | Cyproterone | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.01.03 | Cytarabine | Provider notes
|
| 02.08.02 | Dabigatran | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. See NICE TA for eligibity criteria Provider notes
|
| 08.01.05 | Dabrafenib caps | See NICE TA for eligibility criteria Provider notes
|
| 08.01.05 | Dacarbazine | Provider notes
|
| 05.03.03.02 | Daclatasvir | Provider notes
|
| 08.02.04 | Daclizumab | Provider notes
|
| 08.01.02 | Dactinomycin | Not approved for Relapsed/refractory acute myeloid leukaemia (AML) (JFC October 2016) Provider notes
|
| 05.01.07 | Dalbavancin infusion | Approved if recommended by Microbiology for skin and soft tissue infections in patients only if (JFC April 2017):
Provider notes
|
| 02.08.01 | Danaparoid | Provider notes
|
| 06.07.02 | Danazol | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 10.02.02 | Dantrolene sodium | Provider notes
|
| 15.01.08 | Dantrolene sodium injection | Provider notes
|
| 06.01.02.03 | Dapagliflozin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 05.01.10 | Dapsone | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | Dapsone | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for oral mucosal inflammatory conditions: mucous membrane pemphigoid (MMP), recurrent aphthous stomatitis (RAS) and linear IgA bullous dermatosis (JFC April 2018) Additional information: Transfer of care to GPs after stabilisation in secondary care. Monitoring requirements to be communicated to the GP via letter. Monitoring requirements are FBC and reticulocyte count weekly for four weeks, monthly for 6 months, then every 3 months thereafter. LFTs should be monitored monthly for 3 months, then every 3 months thereafter for duration of therapy. Provider notes
|
| 05.01.07 | Daptomycin | Store in a refrigerator Provider notes
|
| 08.02.04 | Daratumumab injection | See NICE TA for eligibility criteria Provider notes
|
| 09.01.03 | Darbepoetin alfa Aranesp® | Provider notes
|
| 05.03.01 | Darunavir | Provider notes
|
| 05.03.01 | Darunavir + Cobicistat Rezolsta® | Provider notes
|
| 05.03.01 | Darunavir + Cobicistat + Emtricitabine + Tenofovir alafenamide Symtuza® | Approved for HIV infection in line with NHSE commissioning policy F03/P/b (JFC January 2019) Provider notes
|
| 05.03.03.02 | Dasabuvir | Provider notes
|
| 08.01.05 | Dasatinib | Provider notes
|
| 08.01.02 | Daunorubicin | Provider notes
|
| 08.01.02 | Daunorubicin liposomal DaunoXome® | Provider notes
|
| 09.01.03 | Deferasirox | Provider notes
|
| 09.01.03 | Deferiprone | Provider notes
|
| 06.03.02 | Deflazacort |
Provider notes
|
| 08.03.04.02 | Degarelix | Provider notes
|
| 05.01.09 | Delamanid | Approved for XDR-TB and MDR-TB in line with the NHS England Clinical Commissioning Policy F04/P/a (JFC April 2017) Provider notes
|
| 05.01.03 | Demeclocycline | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 06.05.02 | Demeclocycline | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 06.06.02 | Denosumab XGEVA® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for preventing skeletal related events for oncology patients subject to service redevelopment (November 2015) Provider notes
|
| 06.06.02 | Denosumab Prolia® | Approved for osteoporosis in women (see NICE TA) and men unable to take oral bisphosphonates (either due to intolerance or unable to comply with administration instructions) and unable to receive IV zoledronic acid due to renal dysfunction (JFC October 2017) Provider notes
|
| 20 | Denosumab XGEVA® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for hypercalcaemia of malignancy who are either refractory to bisphosphonates or have creatinine clearance <30mL/min in whom bisphosphonates are contraindicated (JFC August 2018). Only on the advice of oncology or palliative care consultants. Provider notes
|
| 07.02.02 | Dequalinium chloride vaginal tablets | Approved for bacterial vaginosis as a second-line alternative to clindamycin 2% intravaginal cream in patients who have not tolerated or failed metronidazole treatment (JFC August 2018). Provider notes
|
| 13.02.01 | Dermamist® spray application | Provider notes
|
| 13.02.02 | Derma-S® barrier preparation | Provider notes
|
| 13.02.01 | Dermatonics Once Heel Balm® Urea 25% | JFC approved for primary and secondary care for treatment of anhidrotic, fissured, calloused and hard foot skin in diabetic patients at high risk of ulceration (March 2018) Provider notes
|
| 13.02.01 | Dermol® 500 lotion | Provider notes
|
| 13.02.01.01 | Dermol® bath/shower additive | Provider notes
|
| 13.02.01 | Dermol® cream | Provider notes
|
| 09.01.03 | Desferrioxamine Mesilate | Provider notes
|
| 18 | Desferrioxamine Mesilate | Provider notes
|
| 15.01.02 | Desflurane | Provider notes
|
| 03.04.01 | Desloratadine | Provider notes
|
| 06.05.02 | Desmopressin | Provider notes
|
| 07.03.02.01 | Desogestrel 75mcg pill generic, Cerazette®, Cerelle®, other brands available | Provider notes
|
| 10.01.02.02 | Dexamethasone | Provider notes
|
| 11.04.01 | Dexamethasone + Framycetin + Gramicidin drops Sofradex® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 12.01.01 | Dexamethasone + Framycetin + Gramicidin drops Sofradex® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 12.01.01 | Dexamethasone + Neomycin + Glacial Acetic Acid ear spray Otomize® | Provider notes
|
| 11.04.01 | Dexamethasone + Neomycin + Polymyxin B drops, ointment Maxitrol® | Provider notes
|
| 12.01.01 | Dexamethasone 0.1% + Ciprofloxacin 0.3% ear drops Cilodex® | Approved for treatment of acute otitis externa with perforated/damaged tympanic membrane (JFC March 2018) Provider notes
|
| 11.04.01 | Dexamethasone 0.1% eye drops | Provider notes
|
| 11.04.01 | Dexamethasone 0.1% eye drops - preservative free | Provider notes
|
| 11.04.01 | Dexamethasone intravitreal implant Ozurdex® |
Provider notes
|
| 06.03.02 | Dexamethasone oral and systemic injection | Provider notes
|
| 04.04 | Dexamfetamine | Provider notes
|
| 15.01.04.04 | Dexmedetomidine injection | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for light sedation (RASS 0 to -3) in mechanically ventilated adult patients with CAM ICU positive agitated delirium where agitation precludes weaning and extubation only after standard sedative agents (including propofol, clonidine or a benzodiazepine) had been trialled for 48 hours. (JFC January 2019). Provider notes
|
| 04.07.02 | Diamorphine | Provider notes
|
| 04.01.02 | Diazepam | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.08.02 | Diazepam | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 10.02.02 | Diazepam | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 15.01.04.01 | Diazepam | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 06.01.04 | Diazoxide | Provider notes
|
| 20 | Dibotermin Alfa, rhBMP-2 Inductos® | Provider notes
|
| 11.03.01 | Dibromopropamidine 0.15% eye ointment | Provider notes
|
| 13.08.01 | Diclofenac 3% gel Solaraze® | Provider notes
|
| 10.01.01 | Diclofenac Sodium | Provider notes
|
| 10.01.01 | Diclofenac sodium + Misoprostol | Provider notes
|
| 11.08.02 | Diclofenac Sodium 0.1% eye drops - single use Voltarol® Ophtha | Provider notes
|
| 10.01.01 | Diclofenac sodium Modified release | Provider notes
|
| 18 | Dicobalt edetate | Provider notes
|
| 01.02 | Dicycloverine | Provider notes
|
| 05.03.01 | Didanosine | Provider notes
|
| 08.03.01 | Diethylstilbestrol | Provider notes
|
| 13.04 | Diflucortolone valerat 0.3% - Topical Nerisone Forte® | Provider notes
|
| 13.04 | Diflucortolone valerate 0.1% - Topical Nerisone® | Provider notes
|
| 02.01.01 | Digoxin | Provider notes
|
| 02.01.01 | Digoxin specific antibody fragments Digifab® | Provider notes
|
| 04.07.02 | Dihydrocodeine | Provider notes
|
| 04.07.02 | Dihydrocodeine modified release | Provider notes
|
| 21.01 | Diltiazem cream | Diltiazem cream for transrectal ultrasound guided prostate biopsy |
| 01.07.04 | Diltiazem Cream 2% | Provider notes
|
| 02.06.02 | Diltiazem immediate release | Provider notes
|
| 02.06.02 | Diltiazem modified release | Prescribe by brand name: modified-release preparations have different release characteristics and are not interchangeable. Provider notes
|
| 08.02.04 | Dimethyl fumarate Tecfidera® | DO NOT CONFUSE Tecfidera® AND Skilarence® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS Provider notes
|
| 13.05.03 | Dimethyl fumarate Skilarence® | DO NOT CONFUSE Tecfidera® AND Skilarence® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS Provider notes
|
| 07.01.01 | Dinoprostone Prostin E2® | Provider notes
|
| 07.01.01 | Dinoprostone Propess® | Provider notes
|
| 14.04 | Diphtheria antitoxin | Provider notes
|
| 13.02.01 | Diprobase® cream | Provider notes
|
| 02.09 | Dipyridamole | See NICE TA for eligibility Provider notes
|
| 11.99.99.99 | Disodium Edetate 0.37% eye drops | Provider notes
|
| 02.03.02 | Disopyramide immediate release | Provider notes
|
| 02.03.02 | Disopyramide modified release | Provider notes
|
| 04.10.01 | Disulfiram | Provider notes
|
| 13.05.02 | Dithranol cream Dithrocream® | Provider notes
|
| 13.05.02 | Dithranol Paste, BP | Provider notes
|
| 02.07.01 | Dobutamine | Provider notes
|
| 08.01.05 | Docetaxel | See NICE TA for eligibility criteria Provider notes
|
| 08.01.05 | Docetaxel + oxaliplatin + disodium folinate + fluorouracil (FLOT) | Approved gastric or gastro-oesophageal junction adenocarcinoma (JFC November 2017) Provider notes
|
| 01.06.02 | Docusate sodium | Provider notes
|
| 05.03.01 | Dolutegravir | Provider notes
|
| 05.03.01 | Dolutegravir + Abacavir + Lamivudine Triumeq® | Approved for HIV in line with NHSE Commissioning Policy B06/P/a. Provider notes
|
| 01.02 | Domperidone | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.06 | Domperidone | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.11 | Donepezil | Provider notes
|
| 02.07.01 | Dopamine | Provider notes
|
| 11.06 | Dorzolamide 2% + Timolol 0.5% eye drops Cosopt® | Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy. Provider notes
|
| 11.06 | Dorzolamide 2% + Timolol 0.5% eye drops - unit dose Cosopt® | Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy. See NCL guideline for place in therapy. Provider notes
|
| 11.06 | Dorzolamide 2% eye drops | See NCL guideline for place in therapy. Provider notes
|
| 11.06 | Dorzolamide 2% eye drops - unit dose | Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. See NCL guideline for place in therapy. Provider notes
|
| 04.03.01 | Dosulepin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.07.04.02 | Dosulepin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 13.02.01 | Doublebase® gel | Provider notes
|
| 03.05.01 | Doxapram | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 15.01.07 | Doxapram | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 02.05.04 | Doxazosin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 07.04.01 | Doxazosin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.01.02 | Doxorubicin | Provider notes
|
| 08.01.02 | Doxorubicin pegylated liposomal Caelyx® | See NICE TA for eligibility criteria Provider notes
|
| 05.01.03 | Doxycycline | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 05.04.01 | Doxycycline | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 02.03.02 | Dronedarone | Provider notes
|
| 06.01.02.03 | Dulaglutide | Semaglutide is the preferred GLP-1 receptor agonist for type 2 diabetes, when used in line with the NCL Fact sheet (JFC August 2019). Dulaglutide should only be initiated for patients (JFC August 2019):
Provider notes
|
| 04.03.04 | Duloxetine Cymbalta® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.07.03 | Duloxetine Cymbalta® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Restricted for patients who cannot tolerate, or have an inadequate response to, gabapentin. Provider notes
|
| 07.04.02 | Duloxetine Yentreve® | Provider notes
|
| A5.02.04 | DuoDERM Extra Thin | Provider notes
|
| 13.05.01 | Dupilumab injection | See NICE TA for eligibility criteria Provider notes
|
| A5.01.02 | Durafiber | Absorbent Cellulose dressing with gel matrix Provider notes
|
| A5.03.03 | Durafiber Ag | Provider notes
|
| 08.01.05 | Durvalumab | See NICE TA for eligibility criteria Provider notes
|
| 20 | Dutasteride | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 13.02.01 | E45® cream | Provider notes
|
| A5.02.03 | Eclypse Adherent | Provider notes
|
| 07.02.02 | Econazole Gyno-Pevaryl® | Provider notes
|
| 11.03.02 | Econazole 1% eye drops | Provider notes
|
| 09.01.03 | Eculizumab | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | Eculizumab | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for 2nd line management of Delayed Haemolytic Transfusion Reactions [DHTRs] hyperhaemolysis in adult Sickle Cell and β-thalassaemia patients who have not responded to IVIG and steroids (pending internal funding approval; JFC July 2019) Provider notes
|
| 02.08.02 | Edoxaban | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. See NICE TA for eligibity criteria Provider notes
|
| 05.03.01 | Efavirenz | Provider notes
|
| 13.09 | Eflornithine 11.5% cream Vaniqa® | Provider notes
|
| 05.03.03.02 | Elbasvir + Grazoprevir | Provider notes
|
| A2.01.01.02 | Elemental 028 ® Extra | Provider notes
|
| 09.08.01 | Eliglustat | Approved for type 1 Gaucher disease, that is, for long-term treatment in adults who are cytochrome P450 2D6 poor, intermediate or extensive metabolisers (JFC November 2017) Provider notes
|
| 09.01.04 | Eltrombopag | Provider notes
|
| 01.04.02 | Eluxadoline | Provider notes
|
| 02.11 | Emicizumab | Provider notes
|
| 06.01.02.03 | Empagliflozin | Provider notes
|
| 05.03.01 | Emtricitabine | Provider notes
|
| 05.03.01 | Emtricitabine + Rilpivirine + Tenofovir disoproxil Eviplera® | Provider notes
|
| 05.03.01 | Emtricitabine + Tenofovir alafenamide Descovy® | Provider notes
|
| 13.02.01.01 | Emulsiderm® liquid emulsion | Provider notes
|
| 13.02.01 | Emulsifying Ointment, BP | Provider notes
|
| 02.05.05.01 | Enalapril | Provider notes
|
| 08.01.05 | Encorafenib caps | See NICE TA for eligibility criteria Provider notes
|
| 05.03.01 | Enfuvirtide | Provider notes
|
| 14.04 | Engerix B® Hepatitis B vaccine Single Component | Provider notes
|
| 02.08.01 | Enoxaparin | Provider notes
|
| 02.01.02 | Enoximone | Provider notes
|
| A2.04.01.02 | Enshake | Provider notes
|
| A2.02.02.03 | Ensure Compact |
Provider notes
Primary care notes Second-choice product - for patients who did not tolerate first-line choices and lower volume is indicated or fluid restricted - see Primary Care Guidance |
| A2.02.02.01 | Ensure Plus Advance | Provider notes
|
| A2.02.02.01 | Ensure Plus Fibre | Provider notes
|
| A2.02.01.02 | Ensure Plus Juce |
Provider notes
Primary care notes Second-choice product - for patients who did not tolerate first-line choices and cannot tolerate milk-based supplements- see Primary Care Guidance |
| A2.02.02.01 | Ensure Plus Milkshake style |
Provider notes
Primary care notes Second-choice product - for patients who did not tolerate first-line choices - see Primary Care Guidance |
| A2.02.02.01 | Ensure Plus Yoghurt style | Provider notes
|
| A2.01.02.03 | Ensure Twocal | Provider notes
|
| 04.09.01 | Entacapone | Provider notes
|
| 05.03.03.01 | Entecavir | Provider notes
|
| 08.03.04.02 | Enzalutamide | Provider notes
|
| 14.04 | Enzira® Influenza vaccine | Provider notes
|
| 13.02.01 | Epaderm® cream/ointment | Provider notes
|
| 02.07.02 | Ephedrine | Provider notes
|
| 12.02.02 | Ephedrine 0.5% nasal drops | Provider notes
|
| 20 | Ephedrine tablets | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.01.02 | Epirubicin | Provider notes
|
| 02.02.03 | Eplerenone | Approved for heart failure in patients unable to tolerate spironolactone due to gynaecomastia (JFC April 2017) Provider notes
|
| 09.01.03 | Epoetin alfa Eprex® | Provider notes
|
| 09.01.03 | Epoetin beta NeoRecormon® | Provider notes
|
| 02.08.01 | Epoprostenol | Approved for pulmonary hypertension (November 2013) Provider notes
|
| 02.09 | Eptifibatide Integrilin® | Provider notes
|
| 09.06.04 | Ergocalciferol | Provider notes
|
| 07.01.01 | Ergometrine Maleate | Provider notes
|
| 07.01.01 | Ergometrine Maleate + Oxytocin Syntometrine® | Provider notes
|
| 04.07.04.01 | Ergotamine Tartrate | Provider notes
|
| 08.01.05 | Eribulin | See NICE TA for eligibility criteria Provider notes
|
| 08.01.05 | Erlotinib | Provider notes
|
| 05.01.02.02 | Ertapenem | Provider notes
|
| 06.01.02.03 | Ertugliflozin tabs | Provider notes
|
| 01.02 | Erythromycin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 05.01.05 | Erythromycin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 11.03.01 | Erythromycin 0.5% eye ointment | Provider notes
|
| 13.06.01 | Erythromycin 40mg + Zinc acetate 12mg/mL topical solution Zineryt® | Provider notes
|
| 04.03.03 | Escitalopram | Provider notes
|
| 02.04 | Esmolol | Provider notes
|
| 01.03.05 | Esomeprazole | Provider notes
|
| 06.04.01.01 | Estradiol Zumenon® | Provider notes
|
| 06.04.01.01 | Estradiol Elleste-Solo® | Provider notes
|
| 07.02.01 | Estradiol 10mcg vaginal tablet Vagifem® | Provider notes
|
| 07.02.01 | Estradiol 7.5mcg /24hrs 7.5 microgram/24 hours vaginal delivery system Estring® | Provider notes
|
| 06.04.01.01 | Estradiol gel Oestrogel® | Approved as hormone replacement therapy for oestrogen deficiency symptoms in postmenopausal women (JFC September 2018). Provider notes
|
| 06.04.01.01 | Estradiol patch Evorel®, FemSeven®, Estradot®, Estraderm MX®, Progynova TS® | Provider notes
|
| 06.04.01.01 | Estradiol with Dydrogesterone Femoston | Provider notes
|
| 06.04.01.01 | Estradiol with Levonorgestrel patch FemSeven® Conti | Provider notes
|
| 06.04.01.01 | Estradiol with Levonorgestrel patch FemSeven® Sequi | Provider notes
|
| 06.04.01.01 | Estradiol with Norethisterone Climesse® | Provider notes
|
| 06.04.01.01 | Estradiol with Norethisterone Elleste-Duet Conti® | Provider notes
|
| 06.04.01.01 | Estradiol with Norethisterone Elleste-Duet® | Provider notes
|
| 06.04.01.01 | Estradiol with Norethisterone Kliofem® | Provider notes
|
| 06.04.01.01 | Estradiol with Norethisterone Kliovance® | Provider notes
|
| 06.04.01.01 | Estradiol with Norethisterone patch Evorel® Conti | Provider notes
|
| 06.04.01.01 | Estradiol with Norethisterone patch Evorel® Sequi | Provider notes
|
| 07.02.01 | Estriol 0.01% vaginal cream Gynest® | Provider notes
|
| 07.02.01 | Estriol 1mg/1g vaginal cream Ovestin® | Provider notes
|
| 10.01.03 | Etanercept | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. JFC approved Benepali as the brand of choice. Approved for:
Provider notes
|
| 13.05.03 | Etanercept | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. JFC approved Benepali as the brand of choice. Provider notes
|
| 20 | Etanercept | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. JFC approved Benepali as the brand of choice. Provider notes
|
| 09.05.01.02 | Etelcalcetide | Provider notes
|
| 05.01.09 | Ethambutol | Provider notes
|
| 06.04.01.01 | Ethinylestradiol | Provider notes
|
| 08.03.01 | Ethinylestradiol | Provider notes
|
| 07.03.01 | Ethinylestradiol / dienogest phased pill 28-days Qlaira® | Provider notes
|
| 07.03.01 | Ethinylestradiol / levonorgestrel phased pill 21-days TriRegol®, Logynon® | Provider notes
|
| 07.03.01 | Ethinylestradiol / levonorgestrel phased pill 28-days Logynon ED® | Provider notes
|
| 07.03.01 | Ethinylestradiol 20 mcg / drospirenone 3 mg Eloine® | Provider notes
|
| 07.03.01 | Ethinylestradiol 20 mcg / norethisterone 1mg pill 21-days Loestrin 20® | Provider notes
|
| 07.03.01 | Ethinylestradiol 20mcg / desogestrel 150mcg pill 21-days Gedarel® 20/150, Mercilon® | Provider notes
|
| 07.03.01 | Ethinylestradiol 20mcg / gestodene 75 mcg pill 21-days Millinette® 20/75, Femodette®, Juliperla®, Sunya 20/75® | Provider notes
|
| 07.03.01 | Ethinylestradiol 30 mcg / norethisterone 1.5mg 21-days Loestrin 30® | Provider notes
|
| 07.03.01 | Ethinylestradiol 30mcg / desogestrel 150mcg pill 21-days Gedarel® 30/150, Marvelon® | Provider notes
|
| 07.03.01 | Ethinylestradiol 30mcg / gestodene 75 mcg pill 21-days Millinette® 30/75, Femodene®, Sofiperla®, Katya 30/75® | Provider notes
|
| 07.03.01 | Ethinylestradiol 30mcg / levonorgestrel 150mcg pill 21-days Rigevidon®, Microgynon 30®, Levest®, Ovranette® | Provider notes
|
| 07.03.01 | Ethinylestradiol 35 mcg / norgestimate 250 mcg pill 21-day Cilique®, Cilest® | Provider notes
|
| 04.08.01 | Ethosuximide | Provider notes
|
| 15.02 | Ethyl Chloride Cryogesic® Spray | econdary care notes
|
| 20 | Etilefrine | Provider notes
|
| 10.01.01 | Etodolac | Provider notes
|
| 10.01.01 | Etodolac Modified Release | Provider notes
|
| 15.01.01 | Etomidate Etomidate-Lipuro® | Provider notes
|
| 15.01.01 | Etomidate Hypnomidate® | Provider notes
|
| 07.03.02.02 | Etonogestrel 68mg subdermal implant Nexplanon® | Second-choice parenteral progestogen-only contraceptive (JFC July 2019) Provider notes
|
| 08.01.04 | Etoposide | Provider notes
|
| 10.01.01 | Etoricoxib | Provider notes
|
| 05.03.01 | Etravirine | Provider notes
|
| 13.02.01 | Eucerin ® Intensive cream/lotion Urea 10% | Provider notes
|
| 08.01.05 | Everolimus Votubia® | DO NOT CONFUSE Afinitor®, Votubia® AND Certican® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS Approved for renal angiomyoplipomas who are at risk of complications but who do not require immediate surgery, and is reserved for patients with multiple AMLs in one or both kidneys and one or more lesions of >3cm in diameter. Restricted to renal consultants in renal genetics specialist clinic only (July 2013) Provider notes
|
| 08.01.05 | Everolimus Afinitor® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. DO NOT CONFUSE Afinitor®, Votubia® AND Certican® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS See NICE TA for eligibility criteriaProvider notes
|
| 02.12 | Evolocumab | Provider notes
|
| 08.03.04.01 | Exemestane | Provider notes
|
| 02.12 | Ezetimibe | Primary hypercholesterolaemia where a statin is contraindicated, not tolerated (consider referral to lipid specialist) or as an adjunct where high-intensity statins have failed to sufficiently reduce cholesterol levels Provider notes
|
| 02.11 | Factor IX | Provider notes
|
| 02.11 | Factor VIIa, recombinant Novo 7® | Provider notes
|
| 02.11 | Factor VIII | Provider notes
|
| 02.11 | Factor VIII + von Willebrand factor | Provider notes
|
| 02.11 | Factor VIII Inhibitor Bypassing Fraction | Provider notes
|
| 02.11 | Factor VIII, recombinant Susoctocog alfa; Obizur® | Provider notes
|
| 02.11 | Factor X Coagadex® | Provider notes
|
| 02.11 | Factor XI Hemoleven® | Provider notes
|
| 02.11 | Factor XIII Fraction, Dried | Provider notes
|
| 05.03.02.01 | Famciclovir | Provider notes
|
| 10.01.04 | Febuxostat | Provider notes
|
| 10.03.02 | Felbinac 3% gel | Provider notes
|
| 02.06.02 | Felodipine | Provider notes
|
| 14.04 | Fendrix® Hepatitis B vaccine Single Component | Provider notes
|
| 02.12 | Fenofibrate | Provider notes
|
| 15.01.04.03 | Fentanyl | Provider notes
|
| 04.07.02 | Fentanyl buccal tablets Effentora® | Provider notes
|
| 04.07.02 | Fentanyl lozenges Actiq® | Provider notes
|
| 04.07.02 | Fentanyl patch | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 21.01 | Fentanyl patch | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Fentanyl patch for acute post-operative pain in primary knee replacement surgery |
| 04.07.02 | Fentanyl sublingual tablets Abstral® | Approved for the treatment of breakthrough, chronic, cancer pain in palliative patients taking opioid agonists, who are unable to obtain relief from, or are intolerant to, oral morphine and oxycodone immediate release. Pain or Palliative Care recommendation only (JFC September 2018). Provider notes
|
| 09.01.01.02 | Ferric Carboxymaltose Ferinject® | See local guidance for iron replacement Approved for:
Provider notes
|
| 17 | Ferric subsulphate solution Monsels | Approved as a haemostatic agent in colposcopy (JFC January 2019) Provider notes
|
| 09.01.01.01 | Ferrous fumarate | Provider notes
|
| 09.01.01.01 | Ferrous fumarate + Folic acid Pregaday® | Provider notes
|
| 09.01.01.01 | Ferrous gluconate | Provider notes
|
| 09.01.01.01 | Ferrous sulphate | Provider notes
|
| 09.01.01.01 | Ferrous sulphate modified release Ferrograd® | Provider notes
|
| 03.04.01 | Fexofenadine | Additionally approved for the treatment of chronic spontaneous urticaria at a 'high dose' for patients who do not respond to 'high dose' cetirizine (JFC November 2018). Notes: initiate at 180mg daily and increase according to response to a maximum of 360mg twice-daily (720mg daily). Provider notes
|
| 17.01 | Fibrin Sealant Evicel® | Approved for Dura matter closure (July 2015)
|
| 17.01 | Fibrin Sealant Tisseel® Ready to Use | Provider notes
|
| 21.01 | Fibrin sealant Artiss® | Simple mastectomies - as part of the '23 hour mastectomy' pathway Provider notes
|
| 05.01.07 | Fidaxomicin | Consultant microbiologist approval only for multiple recurrent Clostridium difficile infections (at least three). Fidaxomicin could also be used in patients in extremis when all other drugs had failed (October 2012) Provider notes
|
| 09.01.06 | Filgrastim | Provider notes
|
| 06.04.02 | Finasteride | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.02.04 | Fingolimod | Provider notes
|
| 07.04.02 | Flavoxate | Provider notes
|
| 02.03.02 | Flecainide | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.07.03 | Flecainide | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 21.01 | Florbetapir F 18 injection | Amyvid (florbetapir) for Alzheimer's disease |
| 17.01 | Flowable haemostatic agent with thrombin Surgiflo® | Approved for complex spinal surgeries. Individual Trusts to decide to choose between Surgilfo and Floseal (choice largely based on acquisition cost and surgeon familiarity) (July 2016) |
| 17.01 | Flowable haemostatic agent with thrombin Floseal® | Approved for complex spinal surgeries. Individual Trusts to decide to choose between Surgilfo and Floseal (choice largely based on acquisition cost and surgeon familiarity) (July 2016) Provider notes
|
| 13.04 | Flucinolone Acetonide 0.0025% - Topical Synalar 1 in 10 Dilution® | Provider notes
|
| 05.01.01.02 | Flucloxacillin | Provider notes
|
| 05.02 | Fluconazole | Provider notes
|
| 05.02 | Flucytosine | Provider notes
|
| 20 | Flucytosine tablets | Provider notes
|
| 08.01.03 | Fludarabine | Provider notes
|
| 06.03.01 | Fludrocortisone | Provider notes
|
| 13.04 | Fludroxycortide - topical Haelan® | Provider notes
|
| 15.01.07 | Flumazenil | Provider notes
|
| 12.01.01 | Flumetasone 0.02% + Clioquinol 1% ear drops Locorten-Vioform® | Provider notes
|
| 12.02.01 | Flunisolide Syntaris® | Provider notes
|
| 13.04 | Fluocinolone acetonide 0.00625% - Topical Synalar 1 in 4 Dilution® | Provider notes
|
| 13.04 | Fluocinolone acetonide 0.025% - Topical Synalar® | Provider notes
|
| 13.04 | Fluocinolone acetonide 0.025% + Clioquinol 3%- Topical Synalar C® | Provider notes
|
| 11.04.01 | Fluocinolone acetonide intravitreal implant Iluvien® |
Provider notes
|
| 13.04 | Fluocinonide 0.05% - Topical Metosyn® | Provider notes
|
| 11.08.02 | Fluorescein eye drops - unit dose | Provider notes
|
| 11.99.99.99 | FluorEscein injection | Provider notes
|
| 11.08.02 | Fluorescein paper strips 1mg | Provider notes
|
| 09.05.03 | Fluorides En-De-Kay® Tablet | Provider notes
|
| 09.05.03 | Fluorides En-De-Kay® Oral Drops | Provider notes
|
| 09.05.03 | Fluorides Duraphat® Toothpaste | Provider notes
|
| 17 | Fluorocholine-18F | Provider notes
|
| 11.04.01 | Fluorometholone 0.1% eye drops FML® | Provider notes
|
| 13.08.01 | Fluorouracil 5% cream Efudix® | Provider notes
|
| 08.01.03 | Fluorouracil injection | Provider notes
|
| 04.03.03 | Fluoxetine | Provider notes
|
| 04.02.02 | Flupentixol decanoate depot injection Depixol® Conc. | Provider notes
|
| 04.02.02 | Flupentixol decanoate depot injection Depixol® Low Volume | Provider notes
|
| 04.02.02 | Flupentixol decanoate depot injection Depixol® | Provider notes
|
| 04.02.01 | Flupentixol tab | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.03.04 | Flupentixol tab | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.02.02 | Fluphenazine decanoate depot injection Modecate® | Provider notes
|
| 04.02.02 | Fluphenazine decanoate depot injection Modecate Concentrate® | Provider notes
|
| 08.03.04.02 | Flutamide | Provider notes
|
| 03.02 | Fluticasone furoate + Umeclidinium + Vilanterol inhaler (DPI) Trelegy® | Approved for COPD when ICS + LAMA + LABA inhalation therapy is indicated, as per NICE guidance (JFC September 2019) Provider notes
|
| 03.02 | Fluticasone furoate + Vilanterol inhaler (DPI) Relvar Ellipta® | Approved for:
Provider notes
|
| 12.02.01 | Fluticasone furoate 27.5mcg/spray nasal spray | Provider notes
|
| 20 | Fluticasone inhaler (DPI) | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved as first-line choice (before budesonide nasules) for eosinophilic oesophagitis in adults. Fluticasone Accuhaler (dry powder inhaler) '250' should be sucked 1-2 doses twice daily and down titrate dose for maintenance dosing (JFC February 2018) Provider notes
|
| 03.02 | Fluticasone inhaler (pMDI + DPI) Flixotide® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 13.04 | Fluticasone propionate - Topical Cutivate® | Provider notes
|
| 03.02 | Fluticasone propionate + Formoterol inhaler (pMDI) Flutiform® | Approved for asthma requiring a combined ICS/LABA (May 2013)
|
| 03.02 | Fluticasone propionate + Salmeterol inhaler (DPI) AirFluSal Forspiro® | Provider notes
|
| 03.02 | Fluticasone propionate + Salmeterol inhaler (pMDI + DPI) Sirdupla®, Seretide® | Provider notes
|
| 12.02.01 | Fluticasone propionate 400mcg/unit nasal drops | Provider notes
|
| 12.02.01 | Fluticasone propionate 50mcg/spray nasal spray | Provider notes
|
| 20 | Fluticasone propionate nasules / nasal spray | Approved for Oral lichen planus after failure of betamethasone (JFC June 2017) Provider notes
|
| 02.12 | Fluvastatin | Provider notes
|
| 04.03.03 | Fluvoxamine Maleate | Provider notes
|
| 09.01.02 | Folic Acid | Provider notes
|
| 08.01.05 | Folinic acid + fluorouracil + irinotecan (FOLFIRI) | Approved for:
Provider notes
|
| 08.01.05 | Folinic acid + fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) | Approved for 1st line treatment of unresectable metastatic colorectal cancer (May 2015) Provider notes
|
| 08.01.05 | Folinic acid + fluorouracil + oxaliplatin + irinotecan (mFOLFIRINOX) | Approved adjuvant treatment of pancreatic cancer (JFC September 2018) Provider notes
|
| 02.08.01 | Fondaparinux | Provider notes
|
| A2.02.02.03 | Foodlink Complete Powder |
Provider notes Non-formulary
Primary care notes First-choice product - see Primary Care Guidance |
| 03.01.01.01 | Formoterol fumarate inhaler (DPI) Oxis® Turbohaler | Provider notes
|
| A2.02.02.03 | Forticreme Complete | Provider notes
|
| A2.02.02.03 | Fortisip Compact Protein | Provider notes
|
| 05.03.01 | Fosamprenavir | Provider notes
|
| 20 | Foscarnet sodium 2% cream | Provider notes
|
| 05.03.02.02 | Foscarnet sodium IV | Provider notes
|
| 05.01.07 | Fosfomycin intravenous | Microbiology approval only for treatment of infections, or suspected infections, caused by multi-drug resistant Gram-negative organisms, including ESBLs (JFC August 2016) Provider notes
|
| 05.01.07 | Fosfomycin oral sachets | Approved for prescribing in primary and secondary care for symptomatic UTI sensitive to fosfomycin, where patients are unable to receive, or the organism is resistant to, first-line antibiotics (July 2015) Provider notes
|
| 08.03.04.01 | Fulvestrant | Approved as Third-line therapy for locally advanced or metastatic HER2-, ER+ breast cancer in postmenopausal women without symptomatic visceral disease, that has recurred or progressed after a non-steroidal aromatase inhibitor and tamoxifen (JFC February 2016). Provider notes
|
| 13.05.02 | Fumaric acid esters Fumaderm ® | Provider notes
|
| 02.02.02 | Furosemide | Provider notes
|
| 11.03.01 | Fusidic Acid 1% gel | Provider notes
|
| 04.07.03 | Gabapentin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Second choice agent for neuropathic pain after first-line amitriptyline. Provider notes
|
| 04.08.01 | Gabapentin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.11 | Galantamine | Provider notes
|
| 04.11 | Galantamine modified release | Provider notes
|
| 11.03.03 | Ganciclovir 0.15% ophthalmic gel |
|
| 11.03.03 | Ganciclovir intravitreal injection | Provider notes
|
| 05.03.02.02 | Ganciclovir IV | Provider notes
|
| 05.03.02.02 | Ganciclovir oral | Provider notes
|
| 14.04 | Gardasil® Human papilloma virus vaccine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for HPV vaccination for MSM (men who have sex with men) in line with Public Health England national immunisation schedule (JFC September 2018). Restricted to GUM and HIV clinics in line with PHE recommendations. Provider notes
|
| 21.01 | Gardasil® Human papillomavirus vaccine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Guardasil (HPV) vaccine for recalcitrant warts |
| 01.01.02 | Gastrocote® | Provider notes
|
| 01.01.02 | Gaviscon Advance® suspension | Provider notes
|
| 01.01.02 | Gaviscon Infant® | Provider notes
|
| 08.01.05 | Gefitinib | Provider notes
|
| 09.02.02.02 | Gelatin intravenous infusion Gelaspan® | Provider notes
|
| 09.02.02.02 | Gelatin intravenous infusion Geloplasma® | Provider notes
|
| 09.02.02.02 | Gelatin intravenous infusion Volplex® | Provider notes
|
| 09.02.02.02 | Gelatin intravenous infusion Gelofusine® | Provider notes
|
| 08.01.03 | Gemcitabine | See NICE TA for eligibility criteria Provider notes
|
| 21.01 | Gemcitabine + oxaliplatin | Gemcitabine + oxaliplatin for biliary tract cancer where cisplatin is contraindicated |
| 11.03.01 | Gentamicin 0.3% drops Ophthalmic | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 12.01.01 | Gentamicin 0.3% drops Ear | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 11.03.01 | Gentamicin Forte 1.5% eye drops | Provider notes
|
| 05.01.04 | Gentamicin injection | Provider notes
|
| 12.03.05 | Glandosane® oral spray | Provider notes
|
| 08.02.04 | Glatiramer acetate | Approve for relapsing-remitting multiple sclerosis inline with NHS England Commissioning (JFC Feb 2016). Brabio® is the preferred brand. Provider notes
|
| 05.03.03.02 | Glecaprevir + Pibrentasvir | Provider notes
|
| 06.01.02.01 | Glibenclamide | Withdrawn from the UK market (November 2019). Provider notes
|
| 06.01.02.01 | Gliclazide | Provider notes
|
| 06.01.02.01 | Glimepiride | Provider notes
|
| 06.01.02.01 | Glipizide | Provider notes
|
| 06.01.04 | Glucagon GlucaGen® HypoKit | Provider notes
|
| A2.07 | Glucose | Provider notes
|
| 06.01.04 | Glucose gel 40% GlucoGel®, Glucoboost®, Dextrogel® | Provider notes
|
| 09.02.02.01 | Glucose Intravenous | Provider notes
|
| 06.01.06 | Glucose urine test strip Diastix® | Provider notes
|
| 13.07 | Glutaraldehyde 10% solution Glutarol® | Provider notes
|
| 01.06.02 | Glycerol (Glycerin) | Provider notes
|
| 11.99.99.99 | Glycerol eye drops | Provider notes
|
| 02.06.01 | Glyceryl trinitrate parenteral | Provider notes
|
| 01.07.04 | Glyceryl Trinitrate rectal ointment | Provider notes
|
| 02.06.01 | Glyceryl trinitrate short-acting (tablets and sprays) | Provider notes
|
| 02.06.01 | Glyceryl trinitrate transdermal | Provider notes
|
| 07.04.04 | Glycine 1.5% Irrigation Solution | Provider notes
|
| 15.01.03 | Glycopyrronium injection | Provider notes
|
| 13.12 | Glycopyrronium powder Robinul® | Provider notes
|
| 13.12 | Glycopyrronium solution for iontophoresis | Provider notes
|
| 13.12 | Glycopyrronium tablets | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | Glycopyrronium tablets | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 01.05.03 | Golimumab | See NCL treatment pathway for place in therapy (note: biosimilar adalimumab and biosimilar infliximab are preferred anti-TNFs; JFC April 2019). Provider notes
|
| 10.01.03 | Golimumab | Approved for:
Provider notes
|
| 06.05.01 | Gonadorelin | Provider notes
|
| 06.07.02 | Goserelin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 06.07.02 | Goserelin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 06.07.02 | Goserelin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.03.04.02 | Goserelin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| A5.02.04 | Granuflex | Provider notes
|
| A5.02.01 | GranuGel | Provider notes
|
| 03.04.02 | Grasses + Rye and Trees Pollen Extract Pollinex® | Approved for grass/tree-pollen seasonal allergic rhinitis requiring treatment with subcutaneous immunotherapy for patients over 6 years old (JFC October 2019). Provider notes
|
| 05.02 | Griseofulvin | Provider notes
|
| 13.10.02 | Griseofulvin 400mcg/spray Grisol AF® | Provider notes
|
| 02.05.03 | Guanethidine monosulfate | Provider notes
|
| 13.05.03 | Guselkumab | Provider notes
|
| 09.08.02 | Haem Arginate Normosang® | Provider notes
|
| 20 | Haemophilus influenzae type B Combined Vaccine Menitorix® | Approved as Test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (JFC May 2017) Provider notes
|
| 01.07.01 | Haemorrhoid relief ointment | Provider notes
|
| 04.02.01 | Haloperidol | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.02.02 | Haloperidol depot injection Haldol Decanoate® | Provider notes
|
| 14.04 | Havrix Monodose® Hepatitis A vaccine Single Component | Provider notes
|
| 14.04 | HBvaxPRO® Hepatitis B vaccine Single Component | Provider notes
|
| 01.03 | Helicobacter Test INFAI | Provider notes
|
| 02.08.01 | Heparin calcium | Provider notes
|
| 02.08.01 | Heparin sodium | Provider notes
|
| 02.08.01 | Heparin sodium flush (10 units / mL) | Provider notes
|
| 13.13 | Heparinoid 0.3% Hirudoid® | Provider notes
|
| 14.05.02 | Hepatitis B immunoglobulin for intramuscular use | Provider notes
|
| 14.05.02 | Hepatitis B immunoglobulin for intravenous use Hepatect® CP | Provider notes
|
| 14.04 | Hepatyrix® Hepatitis A vaccine with typhoid vaccine | Provider notes
|
| 11.03.01 | Hexamidine 0.1% eye drops | Provider notes
|
| 13.10.05 | Histoacryl® | Provider notes
|
| 11.05 | Homatropine 1% eye drops | Provider notes
|
| 11.05 | Homatropine 1% eye drops - preservative free | Provider notes
|
| 02.11 | Human fibrinogen Riastap® | Provider notes
|
| 06.05.01 | Human Menopausal Gonadotrophins Menogon® |
Provider notes
|
| 21.01 | Hyaluronic acid injection Ostenil Plus® | Hyaluronic acid injection (Ostenil Plus) to prevent surgery RNOH: Restricted for use in accordance with the evaluation protocol by consultants in the Shoulder and Elbow Unit |
| 10.03.01 | Hyaluronidase | JFC approved for epidurolysis (epidural lysis of adhesions, adhesiolysis) for the treatment of chronic pain in patients presenting with radicular pain (JFC October 2016) Provider notes
|
| 02.05.01 | Hydralazine | Primary care notes
Provider notes
|
| A5.02.04 | Hydrocoll Border | Provider notes
|
| 13.04 | Hydrocortisone - Topical | Provider notes
|
| 06.03.02 | Hydrocortisone sodium phosphate Efcortesol® | Provider notes
|
| 06.03.02 | Hydrocortisone sodium succinate Solu-Cortef® | Provider notes
|
| 13.04 | Hydrocortisone 0.25% + Crotamiton 10% - Topical Eurax-Hydrocortisone® | Provider notes
|
| 13.04 | Hydrocortisone 0.5% + Nystatin + Benzalkonium + Dimeticone - Topical Timodine® | Provider notes
|
| 13.04 | Hydrocortisone 1% + Clotrimazole 1% - Topical Canesten HC® | Provider notes
|
| 13.04 | Hydrocortisone 1% + Miconazole 2% - Topical Daktacort® | Provider notes
|
| 12.01.01 | Hydrocortisone 1% + Neomycin ear drops Otosporin® | Provider notes
|
| 13.04 | Hydrocortisone 1% + Nystatin + Chlorhexidine - Topical Nystaform-HC® | Provider notes
|
| 13.04 | Hydrocortisone 1% + Urea 10% - Topical Alphaderm® | Provider notes
|
| 10.01.02.02 | Hydrocortisone acetate | Provider notes
|
| 13.04 | Hydrocortisone Acetate 1% + Fusidic Acid 2% - Topical Fucidin H® |
Provider notes
|
| 01.05.02 | Hydrocortisone acetate rectal foam Colifoam® | Provider notes
|
| 12.03.01 | Hydrocortisone buccal tablets | Provider notes
|
| 13.04 | Hydrocortisone butyrate - Topical Locoid® | Provider notes
|
| 11.04.01 | Hydrocortisone sodium phosphate 3.35 mg/ml drops Softacort® | Approved for mild non-infectious allergic or inflammatory ocular surface diseases (JFC September 2019) Provider notes
|
| 06.03.02 | Hydrocortisone tablets | Provider notes
|
| 12.03.04 | Hydrogen peroxide 6% mouthwash BP | Provider notes
|
| 13.11.06 | Hydrogen peroxide cream Crystacide® | Provider notes
|
| 13.11.06 | Hydrogen Peroxide Solution BP | Provider notes
|
| 13.02.01.01 | Hydromol® bath and shower emollient |
Provider notes
|
| 13.02.01 | Hydromol® cream/ointment | Provider notes
|
| 04.07.02 | Hydromorphone injection | Provider notes
|
| 04.07.02 | Hydromorphone modified release Palladone® SR | Provider notes
|
| 09.01.02 | Hydroxocobalamin | Provider notes
|
| 18 | Hydroxocobalamin | Provider notes
|
| 08.01.05 | Hydroxycarbamide | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 09.01.03 | Hydroxycarbamide | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 10.01.03 | Hydroxychloroquine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 13.05.03 | Hydroxychloroquine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for symptomatic erosive oral lichen planus refractory to topical treatment (corticosteroids or tacrolimus) (JFC June 2018). DMARD fact sheet also specifies approval for "Dermatological conditions caused or aggravated by sunlight". Provider notes
|
| 03.04.01 | Hydroxyzine | Provider notes
|
| 01.02 | Hyoscine butylbromide | Provider notes
|
| 15.01.03 | Hyoscine Hydrobromide | Provider notes
|
| 04.06 | Hyoscine hydrobromide patches | Provider notes
|
| 04.06 | Hyoscine hydrobromide tablets | Provider notes
|
| 03.07 | Hypertonic sodium chloride 3% nebuliser solution MucoClear® 3% | Provider notes
|
| 03.07 | Hypertonic sodium chloride 7% nebuliser solution Nebusal® | Provider notes
|
| 11.08.01 | Hypromellose 0.3% + Dextran 70 0.1% eye drops Tears naturale® | Provider notes
|
| 11.08.01 | Hypromellose eye drops | Provider notes
|
| 11.08.01 | Hypromellose eye drops - unit dose | Provider notes
|
| 06.06.02 | Ibandronic Acid 150mg tablets | Provider notes
|
| 06.06.02 | Ibandronic Acid 50mg tablets | Approved as second-line adjuvant therapy for post-menopausal (including those for whom it is chemically induced) women with breast cancer to prevent bone recurrence and cancer mortality, for patients without IV access/zolendronic acid toxicity (JFC February 2019). Provider notes
|
| 06.06.02 | Ibandronic acid IV infusion | Approved for prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases (July 2013). Provider notes
|
| 06.06.02 | Ibandronic Acid IV injection | Provider notes
|
| 08.01.05 | Ibrutinib | Provider notes
|
| 10.03.02 | Ibuprofen 5 % gel | Provider notes
|
| 10.01.01 | Ibuprofen immediate release | Provider notes
|
| 07.01.01.01 | Ibuprofen IV injection Pedea® |
|
| 03.04.03 | Icatibant | Approved for treatment of hereditary angioedema in line with NHS Commissioning Policies (JFC June 2018) Provider notes
|
| 08.01.02 | Idarubicin | Provider notes
|
| 02.08 | Idarucizumab | For dabigatran reversal. Restricted to patients with who have life/limb threatening bleeding, uncontrolled bleeding, or require emergency surgery (February 2016) Provider notes
|
| 08.01.05 | Idelalisib tabs | Idelalisib should not be initiated as a first-line treatment in chronic lymphocytic leukaemia (CLL) patients with 17p deletion or TP53 mutation - see 'Direct Communication' below. See NICE TA for eligibility criteria Provider notes
|
| 09.08.01 | Idursulfase | Provider notes
|
| 08.01.01 | Ifosfamide | Provider notes
|
| 02.05.01 | Iloprost injection | Provider notes
|
| 02.05.01 | Iloprost nebules Ventavis® | Provider notes
|
| 08.01.05 | Imatinib tabs | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Gilvec for GIST only. Generic for all other indications. Provider notes
|
| 09.08.01 | Imiglucerase | Provider notes
|
| 05.01.02.02 | Imipenem + Cilastatin | Provider notes
|
| 04.03.01 | Imipramine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 13.07 | Imiquimod 3.75% cream Zyclara® | Approve for actinic keratosis (AK) and basal cell carcinoma (BCC) (JFC March 2013) Provider notes
|
| 13.07 | Imiquimod 5% cream Aldara® | Provider notes
|
| 14.04 | Inactivated Influenza Vaccine (Split Virion) | Provider notes
|
| A5.03.02 | Inadine (Povidone-iodine) | Provider notes
|
| 02.02.01 | Indapamide | Provider notes
|
| 02.02.01 | Indapamide modified release | Provider notes
|
| 11.08.02 | Indocyanine green | Provider notes
|
| 10.01.01 | Indometacin immediate release | Provider notes
|
| 10.01.01 | Indometacin Modified Release | Provider notes
|
| 20 | Indometacin suppositories | Approved for tocolytic therapy during pre-natal repair of myelomeningocele, a serious form of spina bifida (UCLH only; JFC February 2018) Provider notes
|
| 07.04.01 | Indoramin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 13.11.01 | Industrial Methylated Spirit BP | Provider notes
|
| 14.04 | Infanrix Hexa® Diphtheria, tetanus, pertussis, poliomyelitis (inactivated), hepatitis b (rDNA) and Hib | Provider notes
|
| 14.04 | Infanrix-IPV+Hib® Diphtheria, Tetanus, Pertussis [Acellular, Component], Poliomyelitis [Inactivated] and Haemophilus T | Provider notes
|
| A2.01.03.02 | Infatrini | Provider notes
|
| 01.05.03 | Infliximab | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Remsima is the preferred brand
Provider notes
|
| 10.01.03 | Infliximab | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Remsima is the brand of choice Approved for:
Provider notes
|
| 13.05.03 | Infliximab | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Remsima is the preferred brand Provider notes
|
| 20 | Infliximab | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Remsima is the preferred brand. Approve for steroid-refractory ipilimumab-induced colitis (August 2016) |
| 06.01.01.03 | Injection Devices Autopen® | Provider notes
|
| 06.01.01.03 | Injection Devices HumaPen® Luxura | Provider notes
|
| 04.13 | Inotersen injection | See NICE HST for eligibility criteria Provider notes
|
| 06.01.01.01 | Insulin Humulin® S | Provider notes
|
| 06.01.01.01 | Insulin Actrapid® | Provider notes
|
| 06.01.01.01 | Insulin Aspart NovoRapid® | Provider notes
|
| 06.01.01.02 | Insulin degludec Tresiba® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for patients with Type 1 diabetes who had
Provider notes
|
| 06.01.01.02 | Insulin Detemir Levemir® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 06.01.01.02 | Insulin Glargine 100units/mL Lantus® | For continuation only (new starters to use Abasaglar) Provider notes
|
| 06.01.01.02 | Insulin Glargine 100units/mL Abasaglar® | Approved for:
|
| 06.01.01.01 | Insulin Glulisine Apidra® | Provider notes
|
| 06.01.01.01 | Insulin Lispro 100 units/mL Humalog® | Provider notes
|
| 08.02.04 | Interferon Alfa IntronA® | Provider notes
|
| 08.02.04 | Interferon Alfa Roferon-A® | Provider notes
|
| 08.02.04 | Interferon beta-1a Rebif® | Provider notes
|
| 08.02.04 | Interferon gamma-1b Immukin® | Provider notes
|
| A5.02.01 | Intrasite Gel | Provider notes
|
| 07.03.04 | Intra-uterine Contraceptive Devices TT 380® Slimline | Provider notes
|
| 07.03.04 | Intra-uterine Contraceptive Devices Nova-T® 380 | Provider notes
|
| 07.03.04 | Intra-uterine Contraceptive Devices T-Safe® 380A QuickLoad | Provider notes
|
| 07.03.04 | Intra-uterine Contraceptive Devices Mini TT 380 Slimline® | Provider notes
|
| 07.03.02.03 | Intra-uterine levonorgestrel system Kyleena® | Approved as first-line intra-uterine device for contraception (February 2019) Provider notes
|
| 07.03.02.03 | Intra-uterine levonorgestrel system Jaydess® | Not a recommended intra-uterine device for contraception; Kyleena is preferred (JFC February 2019) Provider notes
|
| 07.03.02.03 | Intra-uterine levonorgestrel system Levosert® | Approved as first-line intra-uterine device for (JFC March 2018):
Provider notes
|
| 07.03.02.03 | Intra-uterine levonorgestrel system Mirena® | Provider notes
|
| 06.02.02 | Iodine and Iodide | Provider notes
|
| 08.01.05 | Ipilimumab | See NICE TA for eligibility criteria Provider notes
|
| 12.02.02 | Ipratropium bromide 0.03% nasal spray | Provider notes
|
| 03.01.02 | Ipratropium inhaler (pMDI) and nebuliser solution | Provider notes
|
| 02.05.05.02 | Irbesartan | Provider notes
|
| 08.01.05 | Irinotecan Hydrochloride | See NICE TA for eligibility criteria Provider notes
|
| 09.01.01.02 | Iron Dextran CosmoFer® | See local guidance for iron replacement Provider notes
|
| 09.01.01.02 | Iron Isomaltoside Monofer® | See local guidance for iron replacement
Provider notes
|
| 09.01.01.02 | Iron Sucrose Venofer® | See local guidance for iron replacement Provider notes
|
| 04.03.02 | Isocarboxazid | Provider notes
|
| 15.01.02 | Isoflurane | Provider notes
|
| 05.01.09 | Isoniazid | Provider notes
|
| 06.01.01.02 | Isophane Insulin Insulatard® | Provider notes
|
| 06.01.01.02 | Isophane Insulin Humulin® I | Provider notes
|
| 02.07.01 | Isoprenaline | Provider notes
|
| 02.06.01 | Isosorbide dinitrate immediate released | Provider notes
|
| 02.06.01 | Isosorbide dinitrate parenteral | Provider notes
|
| 02.06.01 | Isosorbide mononitrate | Provider notes
|
| 13.06.01 | Isotretinoin 0.05% + Erythromycin 2% gel Isotrexin® | Provider notes
|
| 13.06.01 | Isotretinoin 0.05% gel Isotrex® | Provider notes
|
| 13.06.02 | Isotretinoin capsules | Provider notes
|
| 01.06.01 | Ispaghula Husk | Provider notes
|
| 05.02 | Itraconazole | Provider notes
|
| 02.06.03 | Ivabradine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. See NICE TA for eligibility criteria Secondary care notes
|
| 13.06 | Ivermectin 10 mg/g cream | Approve for papulopustular rosacea. Suitable for primary and secondary care initiation (JFC July 2016) Provider notes
|
| 05.05.07 | Ivermectin tablets | Provider notes
|
| 08.01.05 | Ixazomib | See NICE TA for eligibility criteria Provider notes
|
| 10.01.03 | Ixekizumab injection | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. See NICE TA for eligibility criteria Provider notes
|
| 13.05.03 | Ixekizumab injection | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| A2.01.01.01 | Jevity | Provider notes
|
| A2.01.02.01 | Jevity 1.5 kcal | Provider notes
|
| A2.01.02.02 | Jevity Plus | Provider notes
|
| A2.01.02.02 | Jevity Plus HP | Provider notes
|
| A5.02.06 | Kaltostat | Provider notes
|
| 10.03.02 | Kaolin Poultice | Provider notes
|
| 15.01.01 | Ketamine injection | Provider notes
|
| 21.01 | Ketamine oral solution | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Acute pain unresponsive to opiates (inpatient use only; initiation by Pain team consultant or consultant Anaesthetist) |
| 13.10.02 | Ketoconazole 2% cream | Provider notes
|
| 13.09 | Ketoconazole 2% shampoo | Provider notes
|
| 07.02.02 | Ketoconazole 2% vaginal cream Nizoral® | Provider notes
|
| 06.07 | Ketoconazole tablets Ketoconazole HRA® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 21.01 | Ketoconazole tablets | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Ketoconazole for metastatic hormone refractory prostate cancer (third-line and beyond) |
| 06.01.06 | Ketone urine test strips Ketostix® | Provider notes
|
| 15.01.04.02 | Ketorolac | Provider notes
|
| 11.08.02 | Ketorolac 0.5% eye drops Acular® | Approved for:
Provider notes
|
| 11.04.02 | Ketotifen 250mcg/mL eye drops | Provider notes
|
| 11.04.02 | Ketotifen 250mcg/mL eye drops - preservative free | Approved for seasonal allergic conjunctivitis who have an allergy to preservatives within either sodium cromoglicate or olopatadine (JFC July 2019) Provider notes
|
| 02.04 | Labetalol | Provider notes
|
| 04.08.01 | Lacosamide | For patients refractory to standard AEDs (March 2013) Provider notes
|
| 01.06.04 | Lactulose | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 01.06.04 | Lactulose | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 05.03.01 | Lamivudine | Provider notes
|
| 04.02.03 | Lamotrigine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.08.01 | Lamotrigine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.03.04.03 | Lanreotide Somatuline® LA | Provider notes
|
| 08.03.04.03 | Lanreotide Somatuline Autogel® | Provider notes
|
| 01.03.05 | Lansoprazole | Provider notes
|
| 09.05.02.02 | Lanthanum Fosrenol ® | Provider notes
|
| 08.01.05 | Lapatinib | Provider notes
|
| 09.08.01 | Laronidase | Provider notes
|
| 20 | LAT gel (Lidocaine 4% + Adrenaline 0.1% + Tetracaine 0.5%) | Approved for second-line management of pain in children requiring sutures/debridement (JFC February 2018) Provider notes
|
| 11.06 | Latanoprost 0.005% + Timolol 0.5% Xalacom® | Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy. Provider notes
|
| 11.06 | Latanoprost 0.005% eye drops | See NCL guideline for place in therapy. Provider notes
|
| 11.06 | Latanoprost 0.005% eye drops - preservative free | Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes Provider notes
|
| 05.03.03.02 | Ledipasvir + Sofosbuvir | Provider notes
|
| 10.01.03 | Leflunomide | Provider notes
|
| 08.02.04 | Lenalidomide | Provider notes
|
| 09.01.06 | Lenograstim Granocyte® | Provider notes
|
| 08.01.05 | Lenvatinib caps Kisplyx® | DO NOT CONFUSE Kisplyx® AND Lenvima® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS See NICE TA for eligibility criteria Provider notes
|
| 08.01.05 | Lenvatinib caps Lenvima® | DO NOT CONFUSE Kisplyx® AND Lenvima® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS See NICE TA for eligibility criteria Provider notes
|
| 08.03.04.01 | Letrozole | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 20 | Letrozole | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved as a second-line option to induce ovulation in women with WHO group II infertility, following failure of treatment with clomifene citrate (JFC January 2018) Provider notes
|
| 06.07.02 | Leuprorelin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 06.07.02 | Leuprorelin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 06.07.02 | Leuprorelin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.03.04.02 | Leuprorelin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.08.01 | Levetiracetam | Provider notes
|
| 11.06 | Levobunolol 0.5% eye drops | See NCL guideline for place in therapy. Provider notes
|
| 11.06 | Levobunolol 0.5% eye drops - unit dose | See NCL guideline for place in therapy. Provider notes
|
| 15.02 | Levobupivacaine | Provider notes
|
| 15.02 | Levobupivacaine + Fentanyl | Provider notes
|
| 09.08.01 | Levocarnitine | Provider notes
|
| 05.01.12 | Levofloxacin | Provider notes
|
| 11.03.01 | Levofloxacin 5mg/ml eye drops |
|
| 13.03 | Levomenthol in aqueous cream | 0.5%, 1%, 2% Provider notes
|
| 04.02.01 | Levomepromazine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 07.03.05 | Levonorgestrel | Provider notes
|
| 20 | Levosimendan | Approved for acutely decompensated severe chronic heart failure who have failed to respond to conventional therapy and failed to respond to or did not tolerate inotropic agents (dobutamine or enoximone) (JFC July 2017) Provider notes
|
| 06.02.01 | Levothyroxine | Provider notes
|
| 15.02 | Lidocaine + Adrenaline injection Xylocaine® | Provider notes
|
| 12.03.01 | Lidocaine 10% spray Xylocaine® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 15.02 | Lidocaine 10% spray Xylocaine® | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 15.02 | Lidocaine 2% + Chlorhexidine 0.25% gel Instillagel® | Provider notes
|
| 15.02 | Lidocaine 2.5% + Prilocaine 2.5% cream EMLA® | Provider notes
|
| 11.07 | Lidocaine 4% + Fluorescein 0.25% eye drops - unit dose | Provider notes
|
| 15.02 | Lidocaine 4% cream LMX4® | Approved for topical anaesthetic of first-choice prior to venous cannulation or venepuncture for paediatrics (JFC July 2013) Provider notes
|
| 15.02 | Lidocaine 4% solution Laryngojet® | Provider notes
|
| 15.02 | Lidocaine 5% + Phenylephrine 0.5% topical solution | Provider notes
|
| 15.02 | Lidocaine 5% ointment | Provider notes
|
| 20 | Lidocaine infusion | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 02.03.02 | Lidocaine injection | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 15.02 | Lidocaine injection | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 01.06.07 | Linaclotide | Approved for IBS-C in adults where two optimally dosed laxatives (from different classes) and an antispasmodic fail to relieve symptoms. Initiation should be by a Gastroenterologist and reviewed at 4 weeks. Prescribing should be transferred to GPs for ongoing prescribing if found to be effective (JFC May 2017) Provider notes
|
| 05.01.07 | Linezolid | Provider notes
|
| 06.02.01 | Liothyronine | Provider notes
|
| 09.01.06 | Lipegfilgrastim | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Alternative to GCSF + district nurse administration at WH only for patients who can receive daily GCSF but cannot self-inject (JFC August 2016) Provider notes
|
| 13.10.05 | LiquiBand® | Provider notes
|
| 13.02.01 | Liquid and White Soft Paraffin Ointment, NPF | Provider notes
|
| 01.06.03 | Liquid Paraffin | Provider notes
|
| 01.06.04 | Liquid paraffin + Magnesium hydroxide oral emulsion, BP | Provider notes
|
| 11.08.01 | Liquid Paraffin and Liquid Paraffin light eye drops Lacrilube® | Provider notes
|
| A2.04.01.02 | Liquigen | Provider notes
|
| 06.01.02.03 | Liraglutide Victoza® | Semaglutide is the preferred GLP-1 receptor agonist for type 2 diabetes, when used in line with the NCL Fact sheet (JFC August 2019). Liraglutide 1.2mg should only be initiated for patients with concurrent gastrointestinal conditions e.g. inflammatory bowel disease (JFC August 2019). Liraglutide 1.8mg is not recommended (JFC July 2018). Provider notes
|
| 02.05.05.01 | Lisinopril | Provider notes
|
| 04.02.03 | Lithium Carbonate Camcolit® | Provider notes
|
| 04.02.03 | Lithium Carbonate Liskonum® | Provider notes
|
| 04.02.03 | Lithium Carbonate Priadel® | Provider notes
|
| 04.02.03 | Lithium Citrate Li-Liquid® | Provider notes
|
| 04.02.03 | Lithium Citrate Priadel® liquid | Provider notes
|
| 11.04.02 | Lodoxamide 0.1% eye drops | Provider notes
|
| 04.03.01 | Lofepramine | Provider notes
|
| 08.01.01 | Lomustine | Provider notes
|
| 01.04.02 | Loperamide | Provider notes
|
| 05.03.01 | Lopinavir + Ritonavir Kaletra® | Provider notes
|
| 03.04.01 | Loratadine | Provider notes
|
| 04.01.02 | Lorazepam | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 04.08.02 | Lorazepam | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 15.01.04.01 | Lorazepam | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 02.05.05.02 | Losartan | Provider notes
|
| 11.04.01 | Loteprednol eye drops Lotemax® | Provider notes
|
| 03.01.05 | Low range peak flow meter Mini-Wright® | |
| 01.06.07 | Lubiprostone | Provider notes
|
| 08.01.05 | Lutetium (177Lu) oxodotreotide injection | See NICE TA for eligibility criteria Provider notes
|
| 05.01.03 | Lymecycline | Provider notes
|
| 02.05.01 | Macitentan | Provider notes
|
| 01.06.04 | Macrogols Laxido®, Movicol®, Movicol liquid® | Provider notes
|
| 01.06.05 | Macrogols Klean-Prep® | Provider notes
|
| 01.06.05 | Macrogols Moviprep® | Approved for bowel evacuation; first-line bowel cleansing agent (Gastroenterology service). Provider notes
|
| 01.06.04 | Macrogols paediatric | Provider notes
|
| 09.05.01.03 | Magnesium Aspartate Magnaspartate® | Approved for magnesium deficiency (JFC March 2017) Provider notes
|
| 09.05.01.03 | Magnesium glycerophosphate 4mmol/tablet | Provider notes
|
| 01.06.04 | Magnesium Hydroxide Mixture BP | Provider notes
|
| 09.05.01.03 | Magnesium Hydroxide Mixture BP | Provider notes
|
| 20 | Magnesium lactate modified release MagTab® | Provider notes
|
| 09.05.01.03 | Magnesium sulfate injection | Provider notes
|
| 13.10.05 | Magnesium sulfate Paste, BP | Provider notes
|
| 01.01.01 | Magnesium trisilicate Mixture BP | Provider notes
|
| 13.10.04 | Malathion 0.5% liquid Derbac-M® | Provider notes
|
| 03.07 | Mannitol inhalation Bronchitol® | Provider notes
|
| 17 | Mannitol inhalation Osmohale® | Approved for for bronchial challenge testing. For diagnostic use in Lung Function Departments (September 2013) |
| 02.02.05 | Mannitol IV | Provider notes
|
| 05.03.01 | Maraviroc | Provider notes
|
| 21.01 | Maribavir | Maribavir for resistant CMV infections |
| A2.04.01.01 | Maxijul Super Soluble | Provider notes
|
| 05.05.01 | Mebendazole | Provider notes
|
| 01.02 | Mebeverine | Provider notes
|
| 06.04.01.02 | Medroxyprogesterone Acetate | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.03.02 | Medroxyprogesterone acetate | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 07.03.02.02 | Medroxyprogesterone acetate 150mg IM injection Depo-Provera® | First-choice parenteral progestogen-only contraceptive (JFC July 2019) Provider notes
|
| 10.01.01 | Mefenamic Acid | Provider notes
|
| 05.04.01 | Mefloquine | Provider notes
|
| 08.03.02 | Megestrol acetate | Provider notes
|
| 04.01.01 | Melatonin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Initiated by the Sleep Disorder Service, second line for up to 13 weeks, after zopiclone, zolpidem, or a benzodiazepine, and prescribing should not be transferred to primary care. (October 2015) Provider notes
|
| 04.01.01 | Melatonin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for insomnia in learning disability. Specialist initiation and continuation by GP under shared care or fact sheet (JFC October 2016). Provider notes
|
| 04.01.01 | Melatonin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for insomnia in children (> 2 years) with neurological or developmental disorders. Specialist initiation and continuation in primary care (March 2017) Off label use. Provider notes
|
| 04.01.01 | Melatonin | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Approved for:
Provider notes
|
| 04.01.01 | Melatonin Oral Liquid 1mg/1mL | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 10.01.01 | Meloxicam | Provider notes
|
| 08.01.01 | Melphalan | Provider notes
|
| 04.11 | Memantine | Provider notes
|
| 09.06.06 | Menadiol sodium diphosphate | Provider notes
|
| 14.04 | Menitorix® Haemophilus type b and Meningococcal group C conjugate vaccine | Provider notes
|
| 06.05.01 | Menotrophin Merional® | Provider notes
|
| 06.05.01 | Menotrophin Menopur® | Provider notes
|
| 14.04 | Menveo® Meningococcal A, C, W135, and Y conjugate vaccine | Provider notes
|
| 05.04.04 | Mepacrine Hydrochloride | Provider notes
|
| A5.02.03 | Mepitel | Provider notes
|
| 15.02 | Mepivacaine injection Scandonest Plain® | econdary care notes
|
| 03.04.02 | Mepolizumab | Provider notes
|
| 04.07.02 | Meptazinol | Provider notes
|
| 09.08.01 | Mercaptamine Cystagon®, Procysbi® | Provider notes
|
| 01.05.03 | Mercaptopurine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 08.01.03 | Mercaptopurine | NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
| 05.01.02.02 | Meropenem | Provider notes
|
| 01.05.01 | Mesalazine Octasa® | Approved for ulcerative colitis. Octasa is the NCL choice of mesalazine (May 2014, April 2015) Provider notes
|
If used for non-SLS indications
unlicensed
Restricted
Other indications
Restricted This product is currently unavailable in the UK